<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">12703</article-id><article-id pub-id-type="doi">10.7554/eLife.12703</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Mouse models of human <italic>PIK3CA</italic>-related brain overgrowth have acutely treatable epilepsy</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-32244"><name><surname>Roy</surname><given-names>Achira</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32245"><name><surname>Skibo</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32246"><name><surname>Kalume</surname><given-names>Franck</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32247"><name><surname>Ni</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32248"><name><surname>Rankin</surname><given-names>Sherri</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32249"><name><surname>Lu</surname><given-names>Yiling</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32250"><name><surname>Dobyns</surname><given-names>William B</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15958"><name><surname>Mills</surname><given-names>Gordon B</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-8531"><name><surname>Zhao</surname><given-names>Jean J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-5144"><name><surname>Baker</surname><given-names>Suzanne J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-7008"><name><surname>Millen</surname><given-names>Kathleen J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Center for Integrative Brain Research</institution>, <institution>Seattle Children's Research Institute</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Cancer Biology</institution>, <institution>Dana Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Developmental Neurobiology</institution>, <institution>St. Jude Children's Research Hospital</institution>, <addr-line><named-content content-type="city">Memphis</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><label>4</label><institution>The University of Texas MD Anderson Cancer Center</institution>, <addr-line><named-content content-type="city">Houston</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Morrison</surname><given-names>Sean J</given-names></name><role>Reviewing editor</role><aff id="aff5"><institution>Howard Hughes Medical Institute, University of Texas Southwestern Medical Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>kathleen.millen@seattlechildrens.org</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>03</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>4</volume><elocation-id>e12703</elocation-id><history><date date-type="received"><day>29</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>© 2015, Roy et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Roy et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-12703-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.12703.001</object-id><p>Mutations in the catalytic subunit of phosphoinositide 3-kinase (<italic>PIK3CA)</italic> and other PI3K-AKT pathway components have been associated with cancer and a wide spectrum of brain and body overgrowth. In the brain, the phenotypic spectrum of <italic>PIK3CA</italic>-related segmental overgrowth includes bilateral dysplastic megalencephaly, hemimegalencephaly and focal cortical dysplasia, the most common cause of intractable pediatric epilepsy. We generated mouse models expressing the most common activating <italic>Pik3ca</italic> mutations (<italic>H1047R</italic> and <italic>E545K</italic>) in developing neural progenitors. These accurately recapitulate all the key human pathological features including brain enlargement, cortical malformation, hydrocephalus and epilepsy, with phenotypic severity dependent on the mutant allele and its time of activation. Underlying mechanisms include increased proliferation, cell size and altered white matter. Notably, we demonstrate that acute 1 hr-suppression of PI3K signaling despite the ongoing presence of dysplasia has dramatic anti-epileptic benefit. Thus PI3K inhibitors offer a promising new avenue for effective anti-epileptic therapy for intractable pediatric epilepsy patients.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.001">http://dx.doi.org/10.7554/eLife.12703.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.12703.002</object-id><title>eLife digest</title><p>An enzyme called PI3K is involved in a major signaling pathway that controls cell growth. Mutations in this pathway have devastating consequences. When such mutations happen in adults, they can lead to cancer. Mutations that occur in embryos can cause major developmental birth defects, including abnormally large brains. After birth, these developmental problems can cause intellectual disabilities, autism and epilepsy. Children with this kind of epilepsy often do not respond to currently available seizure medications.</p><p>There are several outstanding questions that if answered could help efforts to develop treatments for children with brain growth disorders. Firstly, how do the developmental abnormalities happen? Do the abnormalities themselves cause epilepsy? And can drugs that target this pathway, and are already in clinical trials for cancer, control seizures?</p><p>Now, Roy et al. have made mouse models of these human developmental brain disorders and used them to answer these questions. The mice were genetically engineered to have various mutations in the gene that encodes the catalytic subunit of the PI3K enzyme. The mutations were the same as those found in people with brain overgrowth disorders, and were activated only in the developing brain of the mice. These mutations caused enlarged brain size, fluid accumulation in the brain, brain malformations and epilepsy in developing mice – thus mimicking the human birth defects. The severity of these symptoms depended on the specific mutation and when the mutant genes were turned on during development.</p><p>Next, Roy et al. studied these mice to see if the seizures could be treated using a drug, that has already been developed for brain cancer. This drug specifically targets and reduces the activity of PI3K. Adult mutant mice with brain malformations were treated for just one hour; this dramatically reduced their seizures. These experiments prove that seizures associated with this kind of brain overgrowth disorder are driven by ongoing abnormal PI3K activity and can be treated even when underlying brain abnormalities persist. Roy et al. suggest that drugs targeting PI3K might help treat seizures in children with these brain overgrowth disorders.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.002">http://dx.doi.org/10.7554/eLife.12703.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>PI3K</kwd><kwd>megalencephaly</kwd><kwd>mouse models</kwd><kwd>epilepsy</kwd><kwd>BKM120</kwd><kwd>cortical dysplasia</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Seattle Children's Hydrocephalus Research Guild</institution></institution-wrap></funding-source><award-id>Seattle Children's Hydrocephalus Guild Seed Funds</award-id><principal-award-recipient><name><surname>Millen</surname><given-names>Kathleen J</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01:NS072441</award-id><principal-award-recipient><name><surname>Millen</surname><given-names>Kathleen J</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>CCSG:CA16672</award-id><principal-award-recipient><name><surname>Mills</surname><given-names>Gordon B</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100002736</institution-id><institution>Citizens United for Research in Epilepsy</institution></institution-wrap></funding-source><award-id>SUDEP grant 2014, Christopher Donalty and Kyle Coggins Award</award-id><principal-award-recipient><name><surname>Kalume</surname><given-names>Franck</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01:NS058721</award-id><principal-award-recipient><name><surname>Dobyns</surname><given-names>William B</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01:CA188516</award-id><principal-award-recipient><name><surname>Baker</surname><given-names>Suzanne J</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P50:CA015962-02</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Jean J</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01:CA142536</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Jean J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Acute one-hour treatment of <italic>Pik3ca</italic> mutant mice with a novel anti-epilepsy drug suppresses seizures despite continued developmental brain dysmorphology, promising a new therapeutic strategy for patients with intractable pediatric epilepsy.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The phosphoinositide-3 kinase (PI3K)-AKT pathway is a central player of intracellular signaling, conserved from yeast to mammals. Activating mutations in genes of PI3K-AKT signaling pathway, especially <italic>PIK3CA</italic>, encoding the catalytic p110α isoform of the PI3K complex, have long been linked to cancer (<xref ref-type="bibr" rid="bib12">Cheung and Testa, 2013</xref>; <xref ref-type="bibr" rid="bib20">Engelman, 2009</xref>; <xref ref-type="bibr" rid="bib31">Hennessy et al., 2005</xref>; <xref ref-type="bibr" rid="bib32">Iwabuchi et al., 1995</xref>; <xref ref-type="bibr" rid="bib62">Samuels and Waldman, 2011</xref>; <xref ref-type="bibr" rid="bib29">Gymnopoulos et al., 2007</xref>). Germline and mosaic mutations of <italic>PIK3CA</italic> and other pathway genes also cause a wide range of brain and body overgrowth disorders; all anomalies caused by somatic <italic>PIK3CA</italic> mutations are now collectively termed <italic>PIK3CA</italic>-Related Overgrowth Spectrum (PROS) (<xref ref-type="bibr" rid="bib37">Keppler-Noreuil et al., 2014</xref>). The broad spectrum of brain overgrowth disorders caused by <italic>PIK3CA</italic> activating mutations is impressive. Three strongly activating <italic>PIK3CA</italic> mutations found most commonly in cancer (hotspot mutations) result in severe segmental cortical dysplasia (SEGCD), which includes bilateral dysplastic megalencephaly (MEG), hemimegalencephaly (HMEG) and focal cortical dysplasia (FCD) types 2a/2b (<xref ref-type="bibr" rid="bib42">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="bib17">D'Gama et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Conway et al., 2007</xref>; <xref ref-type="bibr" rid="bib33">Jansen et al., 2015</xref>). Other mutations, resulting in intermediate or weak <italic>PIK3CA</italic> activation, cause MEG or MEG with polymicrogyria (MEG-PMG) as part of the MEG-capillary malformation syndrome (MCAP) (<xref ref-type="bibr" rid="bib15">Conway et al., 2007</xref>; <xref ref-type="bibr" rid="bib51">Mirzaa et al., 2012</xref>; <xref ref-type="bibr" rid="bib57">Rivière et al., 2012</xref>). Developmental features of these brain disorders include cortical malformations, hydrocephalus, Chiari malformation, intellectual disability, autism and epilepsy (<xref ref-type="bibr" rid="bib37">Keppler-Noreuil et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Mirzaa et al., 2012</xref>). FCD represents one of the most common causes of intractable epilepsy (<xref ref-type="bibr" rid="bib5">Bast et al., 2006</xref>; <xref ref-type="bibr" rid="bib21">Fauser et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Fauser, 2006</xref>).</p><p>Conditional mouse alleles for the <italic>H1047R</italic> and <italic>E545K Pik3ca</italic> hotspot mutations have been generated to study tumor formation and assess anti-cancer activities of pathway inhibitors (<xref ref-type="bibr" rid="bib38">Kinross et al., 2012</xref>; <xref ref-type="bibr" rid="bib45">Liu et al., 2011</xref>; <xref ref-type="bibr" rid="bib49">Meyer et al., 2011</xref>; <xref ref-type="bibr" rid="bib58">Robinson et al., 2012</xref>; <xref ref-type="bibr" rid="bib70">Yuan et al., 2013</xref>). To understand the cellular mechanisms behind <italic>PIK3CA</italic>-related brain overgrowth disorders, we used a series of <italic>cre</italic>-drivers to activate expression of <italic>H1047R</italic> and <italic>E545K</italic> alleles in subsets of neural progenitors. Dramatic phenotypes resulted, faithfully modeling the entire spectrum of <italic>PIK3CA</italic>-associated human brain disorders including enlarged brain size, hydrocephalus, cortical dysplasia and epilepsy. The severity of these brain phenotypes critically depended on the <italic>Pik3ca</italic> allele and its time of activation. Notably, <italic>Pik3ca-</italic>associated epilepsy in mice was independent of brain overgrowth and cortical dysplasia. Further the seizures of adult megalencephalic mice were suppressed by acute 1 hr-administration of pan-PI3K inhibitor BKM120 (<xref ref-type="bibr" rid="bib48">Maira et al., 2012</xref>). We conclude that epilepsy in these models represents an active <italic>Pik3ca</italic>-driven process that can be restricted by dynamic modulation of PI3K pathway activity in dysmorphic brains. These results raise the exciting prospect of new molecular based epilepsy therapies in patients whose seizures have been intractable to current anti-seizure therapies.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Megalencephaly caused by Pik3ca overactivation is dependent on both the nature of the mutant allele and its time of overactivation</title><p>Two conditional <italic>Pik3ca</italic> activating alleles (<italic>H1047R</italic> and <italic>E545K)</italic> were crossed with <italic>cre-</italic>drivers to overactivate p110α in progressively restricted sets of neural progenitors and their progeny. The broadest distribution was achieved with <italic>Nestin-cre</italic>, being expressed in nearly all neural progenitors from early embryonic stages. A subset of late embryonic progenitors was targeted by <italic>hGFAP-cre</italic>; while tamoxifen-inducible <italic>Nestin-creER</italic> line drove <italic>cre</italic>-expression in a small subset of neural progenitors around birth. Expression of <italic>H1047R</italic> was dependent upon a tri-allelic system with tet-inducible mutant human cDNA activated by cre-dependent expression of the tet-activator protein (<xref ref-type="bibr" rid="bib45">Liu et al., 2011</xref>) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). The <italic>E545K</italic> mutation was knocked into the endogenous <italic>Pik3ca</italic> locus and a lox-stop-lox cassette introduced upstream of the initiation-coding exon, rendering the mutant allele cre-dependent (<xref ref-type="bibr" rid="bib58">Robinson et al., 2012</xref>). The activity of all cre drivers was confirmed using reporter lines (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>).</p><p>The most severe phenotype was achieved in <italic>hGFAP-cre;H1047R</italic> mutants, when doxycycline was administered from embryonic day (E)0.5. All mutants exhibited progressive hydrocephalus and died prior to weaning. Hydrocephalus was evident as a domed forehead at postnatal day (P)21 (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). Hematoxylin-eosin stained P3 sections showed ventriculomegaly in the megalencephalic <italic>H1047R</italic> mutant brains. Strikingly the hippocampus was not evident in these mutants. Instead, the medial tissue was highly dysplastic with multiple infoldings along its entire length (<xref ref-type="fig" rid="fig1">Figure 1c,d</xref>). In contrast, when pups were treated with doxycycline from P1, no morphological differences were observed between the control and the <italic>hGFAP-cre;H1047R</italic> mutant (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). Thus the effect of <italic>H1047R</italic> mutation on brain size was dependent on time of activation.<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.12703.003</object-id><label>Figure 1.</label><caption><title>Embryonic <italic>Pik3ca</italic> overactivation in mice causes MEG.</title><p>(<bold>a,b</bold>) Compared to control, P21 <italic>hGFAP-cre;H1047R</italic> mutants had domed foreheads. (<bold>c,d</bold>) Coronal section of H&amp;E-stained P3 <italic>H1047R</italic> mutant showed bigger brain and enlarged lateral ventricles compared to control. Mutant neocortex (nctx) was dysplastic and medial tissue highly infolded (arrowhead; d). (<bold>e–g</bold>) P35 <italic>hGFAP-cre;E545K</italic> and <italic>Nestin-cre;E545K</italic> brains were noticeably larger than controls, while <italic>Nestin-creER;E545K</italic> mutants had normal-sized brains compared to controls. Red color of <italic>Nestin-creER;E545K</italic> brain is due to presence of a lox-stop-lox-Tomato reporter allele, and shows successful induction of cre activity. Controls for e,f and g are of genotypes <italic>Pik3ca E545K, hGFAP-cre, Nestin-cre</italic> and <italic>Nestin-creER.</italic> (<bold>h</bold>) MRI volumetric analyses of mutant and corresponding control brains. *p&lt;0.0001; ns, not significant. Each data point in the graph represents 1 mouse. (<bold>i–l</bold>) Nissl-stained coronal sections of representative control and mutant brains. Scale bars: 1 mm (c,d); 2 mm (i-l). See also <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplements 1</xref>–<xref ref-type="fig" rid="fig1s3">3</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.003">http://dx.doi.org/10.7554/eLife.12703.003</ext-link></p></caption><graphic xlink:href="elife-12703-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.12703.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Genetic strategy for <italic>Pik3ca</italic> mouse models.</title><p>(<bold>a</bold>) Schematic of <italic>PIK3CA</italic> functional domains, highlighting positions of <italic>E545K</italic> and <italic>H1047R</italic> activating mutations. (<bold>b</bold>) Genetic strategy for tet-activated <italic>H1047R transgenic</italic> mice (<xref ref-type="bibr" rid="bib45">Liu et al., 2011</xref>): the human H1047R mutation was activated in the combined presence of cre recombinase and doxycycline (dox). rtTA, reverse tetracycline-controlled transactivator. (<bold>c</bold>) Genetic strategy for <italic>E545K</italic> conditional knock-in mice (<xref ref-type="bibr" rid="bib58">Robinson et al., 2012</xref>): exon 9 of PIK3CA gene was replaced by an exon containing <italic>E545K</italic> mutation; and a STOP cassette flanked by loxP recombination sites is introduced in the intron immediately upstream of the exon encoding the transcription initiation site. Cre recombination resulted in removal of STOP cassette, allowing the transcription of the mutant <italic>E545K</italic> allele.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.004">http://dx.doi.org/10.7554/eLife.12703.004</ext-link></p></caption><graphic xlink:href="elife-12703-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.12703.005</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Expression of <italic>cre</italic> lines.</title><p>Table of <italic>cre</italic> expression for (<bold>a</bold>) <italic>Nestin-cre</italic>, (<bold>b</bold>) <italic>hGFAP-cre</italic> and (<bold>c</bold>) <italic>Nestin-creER</italic> induced by tamoxifen at P0 and P1, using Ai14 and <italic>Rosa26-LacZ</italic> reporter lines.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.005">http://dx.doi.org/10.7554/eLife.12703.005</ext-link></p></caption><graphic xlink:href="elife-12703-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.12703.006</object-id><label>Figure 1—figure supplement 3.</label><caption><title>Neonatal activation of <italic>H1047R</italic> mutation show no effect on brain morphology</title><p><italic>hGFAP-cre;H1047R</italic> mutant display normal brain morphology, when doxycycline was administered postnatally from P1. Scale bar: 2 mm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.006">http://dx.doi.org/10.7554/eLife.12703.006</ext-link></p></caption><graphic xlink:href="elife-12703-fig1-figsupp3-v2.tif"/></fig></fig-group></p><p><italic>E545K</italic> mice with the same <italic>cre-</italic>driver (<italic>hGFAP-cre;E545K)</italic> had a milder phenotype, surviving as adults without hydrocephalus, though their brain size was significantly larger compared to control littermates (<xref ref-type="fig" rid="fig1">Figure 1e,h,j</xref>). This provides evidence that with identical time of activation by the same cre driver, the brain phenotypes are dependent on specific <italic>Pik3ca</italic> allele. Earlier activation of <italic>E545K</italic> mutation with <italic>Nestin-cre</italic> led to an even more striking 54.4% volumetric increase, with mild ventriculomegaly and no hydrocephalus (<xref ref-type="fig" rid="fig1">Figure 1f,h,k</xref>). Interestingly, neonatal activation of <italic>E545K</italic> using <italic>Nestin-creER</italic> had no apparent impact on brain size (<xref ref-type="fig" rid="fig1">Figure 1g,h,l</xref>). Enlarged head size in both <italic>Nestin-cre;E545K</italic> and <italic>hGFAP-cre;E545K</italic> mutants was evident at birth and brain size of all the three adult <italic>E545K</italic> mutants was relatively stable (data not shown). Unlike <italic>H1047R</italic> mutants, gross morphology was normal for all <italic>E545K</italic> mutants. We conclude that brain phenotypes caused by Pik3ca-overactivation are both allele and time dependent. Further, we conclude that to cause brain overgrowth, overactivation of Pik3ca function is required during embryogenesis.</p></sec><sec id="s2-2"><title>Multiple allele-dependent embryonic mechanisms drive <italic>Pik3ca-</italic>MEG</title><p>To assess the mechanisms causing Pik3ca-dependent embryonic brain enlargement, we focused our analysis on <italic>hGFAP-cre;H1047R</italic> (doxycycline from E0.5) and <italic>Nestin-cre;E545K</italic> mutants, since these allelic combinations had the most extreme megalencephalic phenotypes.</p><p>The inner cortical length of <italic>hGFAP-cre;H1047R</italic> mutants was longer than controls at both E14.5 (p&lt;0.01) and E16.5 (p&lt;0.001; <xref ref-type="fig" rid="fig2">Figure 2b–g</xref>). This was accompanied by enlarged nuclear and cell size at both ages and decreased cell density at E16.5, but not increased proliferation or cell cycle exit (<xref ref-type="fig" rid="fig3">Figure 3c–l</xref>). Total cell number per cortical column length was not significantly different between control and <italic>H1047R</italic> mutant both at E14.5 and E16.5. Also, TUNEL<sup>+</sup> cell number was significantly lower in E16.5 mutant cortex than in control (p&lt;0.01), indicating reduced apoptosis (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1a,c</xref>); however the overall TUNEL<sup>+</sup> cell numbers for both control and mutant were small. Together these results indicate that cortical expansion in <italic>hGFAP-cre;H1047R</italic> mutant was not primarily driven by increased proliferation or reduced apoptosis; rather reduced cell density and increased cell size during embryogenesis were major contributing factors.<fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.12703.007</object-id><label>Figure 2.</label><caption><title><italic>Pik3ca</italic> activating mutations lead to increased embryonic cortical length.</title><p>(<bold>a</bold>) Schematic shows how cortical length and thickness were measured. F, fimbria/cortical hem. Nissl-stained coronal sections of control (b,e,h,k) and mutant (c,f,I,l) brains. (<bold>b–g</bold>) Cortical length of <italic>hGFAP-cre;H1047R</italic> mutant at E14.5 and E16.5 was longer than control; cortical thickness was not different. (<bold>h–m</bold>) Cortical length of <italic>Nestin-cre;E545K</italic> mutant was longer than control at E16.5 but not at E14.5; thickness was not different at E14.5 but was smaller than control at E16.5. Data are represented as mean ± SEM. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001. Scale bars: 300 μm (b,c,e,f,h,i,k,l).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.007">http://dx.doi.org/10.7554/eLife.12703.007</ext-link></p></caption><graphic xlink:href="elife-12703-fig2-v2.tif"/></fig></p><p>By contrast, in <italic>Nestin-cre;E545K</italic> mutants, the inner cortical length was comparable to controls at E14.5 but elongated at E16.5 (p&lt;0.01); cortical thickness was slightly reduced in E16.5 (p&lt;0.05) as compared to controls (<xref ref-type="fig" rid="fig2">Figure 2h–m</xref>). The labeling index was similar to the control at E14.5 but increased in E16.5 mutants (p&lt;0.05), indicating more proliferation (<xref ref-type="fig" rid="fig3">Figure 3m,o,r</xref>). Cell density in <italic>E545K</italic> mutant neocortex was similar to the control at E14.5 but was reduced at E16.5 (p&lt;0.05). Total cells per cortical column length did not change in the <italic>E545K</italic> mutant; but the TUNEL<sup>+</sup> cell number was lower in E16.5 mutant cortex than in control (p&lt;0.001). Intriguingly, the nuclear size of these mutant cells was similar to controls at both E14.5 and E16.5 but cell somas were significantly larger (p&lt;0.05) at E16.5 (<xref ref-type="fig" rid="fig3">Figure 3n,p,q,s,t</xref>). The quit fraction indicative of rate of cells exiting cell cycle was significantly higher (p&lt;0.05) in the <italic>E545K</italic> mutant between E15.5 and E16.5 (<xref ref-type="fig" rid="fig3">Figure 3u,v</xref>). At P35, the neocortical cells of <italic>Nestin-cre;E545K</italic> mutant were still larger (p&lt;0.05) compared to controls (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2a,b</xref>). Notably, in the adult P35 <italic>Nestin-creER;E545K</italic> mutant mice, where activation was initiated in neonates, and brain size was not different from controls, <italic>E545K</italic>-activated (YFP+) cells have the same size as controls (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2c,d</xref>). We conclude that increased cell size due to <italic>E545K</italic> overactivation also has a critical embryonic period. Further, changes in multiple developmental parameters including proliferation, cell cycle exit, cell size and density contribute to MEG of <italic>Nestin-cre;E545K Pik3ca</italic> embryonic overactivation.<fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.12703.008</object-id><label>Figure 3.</label><caption><title><italic>H1047R</italic> and <italic>E545K</italic> mutations differentially affect proliferation, cell density and size in neocortex.</title><p>(<bold>a</bold>) Schematic shows area of interest (red box) in E16.5 mouse coronal section, as depicted in c,d,k,m,n,u. (<bold>b</bold>) Experimental outline of the proliferation and cell cycle exit assays. For labeling index, E14.5 and E16.5 control and mutant brains, harvested after a 1hr BrdU pulse, were processed for BrdU and DAPI staining (<bold>c,m</bold>). For quit fraction analysis, E16.5 control and mutant brains, pulsed with BrdU at E15.5, were processed for BrdU and Ki67 (<bold>k,u</bold>). Magnified view of DAPI-stained cortical nuclei shows differences in size and density between controls and mutants (<bold>d,n</bold>). (<bold>e-j,l</bold>) E14.5 and E16.5 <italic>H1047R</italic> mutants had similar labeling indices (BrdU<sup>+</sup> cells/total DAPI<sup>+</sup> cells); E16.5 <italic>H1047R</italic> mutant neocortex displayed reduced cell density (x10<sup>5</sup> DAPI<sup>+</sup> cells/mm<sup>3</sup> volume), larger nuclear and cell size (μm<sup>2</sup>) and similar quit fraction (BrdU<sup>+</sup>Ki67<sup>-</sup> cells/total BrdU<sup>+ </sup>cells). (<bold>o-q</bold>) E14.5 <italic>E545K</italic> mutant neocortex was similar to control in labeling index, cell density and nuclear size. (<bold>r-t,v</bold>) E16.5 <italic>E545K</italic> mutant showed significantly higher labeling index and quit fraction, reduced cell density, and enlarged cell and nuclear size, compared to controls. Data are represented as mean ± SEM (e,f,h,i,I,o,p,r,s,v) or as median-centered box-and-whisker plots (g,j,q,t); *p&lt;0.05; **p&lt;0.001; ***p&lt;0.0001. Scale bars: 50 μm (c,d,m,n); 100 μm (k,u). See also <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplements 1</xref>–<xref ref-type="fig" rid="fig3s2">2</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.008">http://dx.doi.org/10.7554/eLife.12703.008</ext-link></p></caption><graphic xlink:href="elife-12703-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.12703.009</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Effect of <italic>PIK3CA</italic> mutations on total cell numbers and apoptosis.</title><p>(<bold>a,b</bold>) No significant differences in the total cell numbers per cortical column length were observed in <italic>Nestin-cre;E545K</italic> and <italic>hGFAP-cre;H1047R</italic> mutants when compared with their respective control littermates, both at E14.5 and E16.5. (<bold>c,d</bold>) TUNEL-positive cell number at E16.5 is significantly lower in <italic>Nestin-cre;E545K</italic> and <italic>hGFAP-cre;H1047R</italic> mutants than the respective controls. *p&lt;0.01; **p&lt;0.001.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.009">http://dx.doi.org/10.7554/eLife.12703.009</ext-link></p></caption><graphic xlink:href="elife-12703-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.12703.010</object-id><label>Figure 3—figure supplement 2.</label><caption><title><italic>E545K</italic> mutation affects cell size when activated embryonically but not postnatally.</title><p>(<bold>a</bold>) Cells of P35 control and <italic>Nestin-cre;E545K</italic> mutant neocortex are marked by pS6. (<bold>b</bold>) Cell size of P35 <italic>E545K</italic> mutant was significantly larger than that of control littermate. (<bold>c</bold>) YFP-positive cells of P51 control (<italic>Nestin-creER;YFP</italic>) and mutant (<italic>Nestin-creER; E545K;YFP</italic>), induced by tamoxifen at P0 and P1 are the cre-recombined cells, DAPI stains the nuclei. (<bold>d</bold>) Size of these cells was not significantly different between the control and <italic>Nestin-creER;E545K</italic> mutants. Data are represented as median-centered box-and-whisker plot (<bold>b,d</bold>). white open arrows, control cells; white arrowheads, mutant cells. Scale bars: 100 μm (a,c).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.010">http://dx.doi.org/10.7554/eLife.12703.010</ext-link></p></caption><graphic xlink:href="elife-12703-fig3-figsupp2-v2.tif"/></fig></fig-group></p></sec><sec id="s2-3"><title>Embryonic <italic>Pik3ca</italic> activation results in cortical dysplasia</title><p>Since disordered lamination is a key feature of human SEGCD (<xref ref-type="bibr" rid="bib2">Arai et al., 2012</xref>; <xref ref-type="bibr" rid="bib59">Rossini et al., 2014</xref>), we assessed neocortical organization and development in both <italic>hGFAP-cre;H1047R</italic> and <italic>Nestin-cre;E545K</italic> mutants. First, we studied the effect of <italic>Pik3ca</italic> overactivation on the Nestin-positive radial glial fibers, the scaffold for glial-guided neuronal migration, at multiple developmental stages. In <italic>H1047R</italic> mutants, the radial glial scaffold was slightly fasciculated and irregular at E14.5 and E16.5. Irregularities were very prominent at P0 when a disrupted pial surface was associated with irregular clusters of enlarged radial glial end-feet (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). The radial glial phenotype was much more subtle in the <italic>E545K</italic> mutant at E14.5 and E16.5; however at P0, we observed thinning of radial glial fibers and irregular clusters of end-feet at the intact pial surface (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>).</p><p>Cajal-Retzius cells expressing Reelin, a major regulator of radial migration, were normally present in an ordered array in the marginal zone (layer I) of controls and <italic>Nestin-cre;E545K</italic> mice (<xref ref-type="fig" rid="fig4">Figure 4b</xref>; <xref ref-type="fig" rid="fig5">Figure 5b,c</xref>). However, these cells were dysplastic in <italic>hGFAP-cre;H1047R</italic> mice at E16.5 (<xref ref-type="fig" rid="fig4">Figure 4c,c’</xref>). We did not observe ectopic Reelin-positive cells within the cortical column in either mutant. As expected, within the developing wildtype neocortex, Ctip2 and Tbr1 were expressed predominantly in the early-born, deep layers (layers V-VI), while Cux1 was expressed in late-born upper layers (layers II-IV). <italic>hGFAP-cre;H1047R</italic> mutants displayed a marked disorganization of all layers. Ctip2/Tbr1-positive as well as Cux1-positive cells in the E16.5 <italic>H1047R</italic> mutant were dispersed throughout the cortical plate, with both early- and late-born neurons severely mislocalized (<xref ref-type="fig" rid="fig4">Figure 4d–g</xref>). Laminar disorganization was less severe in E16.5 <italic>Nestin-cre;E545K brains</italic>, but deep Ctip2/Tbr1-positive neurons and upper Cux1-positive neurons were dispersed throughout the cortical plate (<xref ref-type="fig" rid="fig5">Figure 5f,g</xref>).<fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.12703.011</object-id><label>Figure 4.</label><caption><title><italic>H1047R</italic> mutant mice display abnormal neocortical layering.</title><p>(<bold>a</bold>) Schematics of mouse brain and section; section corresponds to the marked coronal plane; red box in the section marks the area of neocortex (nctx) depicted in the images below. (<bold>b<bold>–</bold>g</bold>) and (<bold>h–m</bold>) correspond to ages E16.5 and P3 respectively. In control cortex, Reelin is in layer I (<bold>b</bold>), Ctip2 and Tbr1 in deep layers VI and V (d,j), Cux1 in upper layers II-IV (<bold>f,l</bold>) and NeuN in all matured neurons (<bold>h</bold>). <italic>H1047R</italic> mutants displayed abnormal distribution of cells for all neocortical layers, observed at E16.5 and P3 (c,e,g,i,k,m). (<bold>b’,c’</bold>) Magnified view of Reelin-positive cells in control and <italic>H1047R</italic> mutant. P3 <italic>H1047R</italic> mutant showed enlarged area between ventricular zone (vz) and cortical plate and absence of clear subplate (sp) boundary (h-k). A, anterior; P, posterior; yellow dashed lines, lateral ventricular lining; white dotted lines, pial surface; I-VI, neocortical layers; arrowheads, mispositioned mutant cells. Scale bars: 25 μm (b’,c’), 50 μm (b-i), 150 μm (j-o). See also <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref>–<xref ref-type="fig" rid="fig4s2">2</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.011">http://dx.doi.org/10.7554/eLife.12703.011</ext-link></p></caption><graphic xlink:href="elife-12703-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.12703.012</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Nestin expression in <italic>hGFAP-cre; H1047R</italic> mutant.</title> <p>Nestin-positive radial glial fibres appeared slightly irregular and hyperfasciculated in E14.5 <italic>H1047R</italic> mutant (<bold>b</bold>) but show progressively dysplastic morphology at E16.5 (<bold>d</bold>) and P0 (<bold>f</bold>), compared to respective controls (<bold>a,c,e</bold>). Yellow boxes (<bold>e,f</bold>) show broken pia and disrupted radial glial end-feet in the P0 <italic>H1047R</italic> mutant (<bold>f</bold>). Arrows indicate Nestin-fibers crossed the broken pial surface in the mutant. Scale bars: 50 μm (a,b), 150 μm (c-f).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.012">http://dx.doi.org/10.7554/eLife.12703.012</ext-link></p></caption><graphic xlink:href="elife-12703-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.12703.013</object-id><label>Figure 4—figure supplement 2.</label><caption><title><italic>hGFAP-cre;H1047R</italic> mutant displays distinct white matter dysplasia.</title><p>Nissl-stained coronal sections of P3 control (a,c,e) and mutant (b,d,f) brains; areas with faint or absence of Nissl stain consist of axon fibre tracts. (<bold>a,b</bold>) and (<bold>c,d</bold>) show two comparable antero-posterior planes of section between control and <italic>H1047R (hGFAP-cre;H1047R)</italic> mutant. (<bold>a,c</bold>) P3 Control sections showed presence of anterior commissure (black arrow), corpus callosum (cc) and hippocampal commissure (hc). <italic>H1047R</italic> mutants lacked corpus callosum (asterisk, b) while other commissures were present (<bold>d</bold>). Magnified view of neocortex showed expansion of white matter (wm) areas in <italic>H1047R</italic> mutant compared to control (<bold>e,f</bold>). (<bold>e<sub>i</sub></bold>) and (<bold>f<sub>i</sub></bold>) correspond to the dotted boxes in e and f respectively, illustrating presence of increased number of Olig2-positive cells in the expanded white matter area of <italic>H1047R</italic> mutant. The mutant also had an unclear subplate boundary (white dotted line; f, f<sub>i</sub>), which is normally seen in the control (sp; e, e<sub>i</sub>). CP, cortical plate; vz, ventricular zone. Scale bars: 50 μm (e<sub>i</sub>,f<sub>i</sub>); 300 μm (e,f); 1 mm (a-d).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.013">http://dx.doi.org/10.7554/eLife.12703.013</ext-link></p></caption><graphic xlink:href="elife-12703-fig4-figsupp2-v2.tif"/></fig></fig-group><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.12703.014</object-id><label>Figure 5.</label><caption><title><italic>E545K</italic> mutant mice display abnormal neocortical upper layers.</title><p>(<bold>a</bold>) Schematics of mouse brain and section; section corresponds to the marked coronal plane; red box marks the area of neocortex (nctx) depicted in the images below. (<bold>b-g</bold>) and (<bold>h-m</bold>) correspond to ages E16.5 and P35 respectively. (<bold>b-g</bold>) Compared to control, in E16.5 <italic>E545K</italic> mutant, layer I appeared normal; deep layers lacked normal arrangement while Cux1-positive cells were dispersed throughout the cortical plate. Extent of dispersion was reduced postnatally (h-m). vz, ventricular zone; yellow dashed lines, lateral ventricular lining; white dotted lines, pial surface; I-VI, neocortical layers; arrowheads, mispositioned mutant cells. Scale bars: 50 μm (b-g), 150 μm (h-m). See also <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref>–<xref ref-type="fig" rid="fig5s3">3</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.014">http://dx.doi.org/10.7554/eLife.12703.014</ext-link></p></caption><graphic xlink:href="elife-12703-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.12703.015</object-id><label>Figure 5—figure supplement 1.</label><caption><title>: Nestin expression in <italic>Nestin-cre;E545K</italic> mutant.</title><p>Nestin-positive radial glial fibres appeared normal in E14.5 and E16.5 <italic>Nestin-cre;E545K</italic> mutant (<bold>b,d</bold>) but subtle abnormalities in the glial end-feet were observed at P0 (asterisks, <bold>f</bold>), compared to respective controls (<bold>a,c,e</bold>). Scale bars: 50 μm (a,b), 150 μm (c-f).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.015">http://dx.doi.org/10.7554/eLife.12703.015</ext-link></p></caption><graphic xlink:href="elife-12703-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.12703.016</object-id><label>Figure 5—figure supplement 2.</label><caption><title><italic>Nestin-cre;E545K</italic> mutant displays distinct white matter dysplasia.</title><p>(<bold>a,b</bold>) P3 <italic>Nestin-cre;E545K</italic> mutants had all three major commissures as in control littermates. (<bold>c,d</bold>) The mutant corpus callosum as well as the corona radiata were thickened compared to controls. c<sub>i</sub>, c<sub>ii</sub>, d<sub>i</sub> and d<sub>ii</sub> correspond to the dotted boxes in (<bold>c</bold>) and (<bold>d</bold>) respectively. <italic>E545K</italic> mutants had increased numbers of Olig2-positive cells in an expanded corpus callosum (<bold>d<sub>i</sub></bold>) and lateral fiber tract (<bold>d<sub>ii</sub></bold>) with respect to the respective controls (<bold>c</bold><sub><bold>i</bold>,</sub><bold>c<sub>ii</sub></bold>). The subplate in the <italic>E545K</italic> mutant though defined was less packed than the control. CP, cortical plate; cc, corpus callosum; hc, hippocampal commissure; sp, subplate. Scale bars: 50 μm (c<sub>i</sub>,c<sub>ii</sub>,d<sub>i</sub>,d<sub>ii</sub>); 1 mm (a-d).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.016">http://dx.doi.org/10.7554/eLife.12703.016</ext-link></p></caption><graphic xlink:href="elife-12703-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.12703.017</object-id><label>Figure 5—figure supplement 3.</label><caption><title>Astrocytes show no gross dysmorphology in adult <italic>Nestin-cre;E545K</italic> and <italic>Nestin-creER;E545K</italic> mutants.</title><p>S100 is expressed in astrocytes (<bold>a-d</bold>). No gross change in morphology or number was observed in the <italic>Nestin-cre;E545K</italic> and <italic>Nestin-creER;E545K;YFP</italic> mutants compared to controls. Insets (<bold>a,b</bold>) show magnified cells. Scale bars: 100 μm (a-d).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.017">http://dx.doi.org/10.7554/eLife.12703.017</ext-link></p></caption><graphic xlink:href="elife-12703-fig5-figsupp3-v2.tif"/></fig></fig-group></p><p>Laminar patterns in postnatal animals remained disrupted in both mutants, with <italic>hGFAP-cre;H1047R</italic> cortex more affected <italic>Nestin-cre;E545K</italic> mutant cortex (<xref ref-type="fig" rid="fig5">Figure 5h–m</xref>). Thus a simple developmental delay was not the cause of dysplasia (<xref ref-type="fig" rid="fig4">Figure 4h–m</xref>; <xref ref-type="fig" rid="fig5">Figure 5h–m</xref>). In P3 <italic>hGFAP-cre;H1047R</italic> mutants, NeuN-positive mature cortical neurons were found within the normally cell-sparse marginal zone as well as in the cortical white matter and residual ventricular zone, a feature reported in SEGCD patients (<xref ref-type="bibr" rid="bib2">Arai et al., 2012</xref>). Further, the cortical subplate was not readily discernible in these mutants (<xref ref-type="fig" rid="fig4">Figure 4h–k</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2e,f</xref>), blurring the boundary between grey and white matter – a feature often observed in SEGCD patients (<xref ref-type="bibr" rid="bib59">Rossini et al., 2014</xref>).</p><p>To determine whether the mislocalization of neocortical cells was due to defects in cell fate specification and/or migration, we labeled cells at either E12.5 or at E16.5 with pulse of BrdU and assessed cortical neuronal location and fate (layer V; Ctip2<sup>+</sup> and layers II/III; Cux1<sup>+</sup>) (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). The total numbers of BrdU<sup>+</sup> P0 cells, born at E12.5 and E16.5, were not significantly different between controls and either <italic>hGFAP-cre;H1047R</italic> or <italic>Nestin-cre;E545K</italic> mutants (<xref ref-type="fig" rid="fig6">Figure 6b,j</xref>). The distribution of BrdU<sup>+</sup> cells showed significant differences between controls and <italic>H1047R</italic> mutants labelled during both early and late embryonic stages. At P0, more BrdU<sup>+</sup> cells were localized in the lower cortical plate (CP) and white matter (<xref ref-type="fig" rid="fig6">Figure 6c</xref>). For <italic>E545K</italic> mutants the BrdU<sup>+</sup> cell numbers were not different at either age. The distribution was subtly, yet significantly different only for the early born neurons (<xref ref-type="fig" rid="fig6">Figure 6k</xref>). For both the <italic>H1047R</italic> and <italic>E545K Pik3ca</italic> activating alleles, total layer V (Ctip2<sup>+</sup>) cell numbers at P0 were not significantly different between controls and mutants (<xref ref-type="fig" rid="fig6">Figure 6d,l</xref>). Also, the numbers of Ctip2/BrdU double-labeled cells were the same in controls and mutants, indicating that cell fate specification for these deep layer neurons was unaffected by either the <italic>H1047R</italic> or <italic>E545K Pik3ca</italic> allele (<xref ref-type="fig" rid="fig6">Figure 6e,m</xref>). However, similar to the overall BrdU<sup>+</sup> cell distribution, the specific distribution of layer V neurons was abnormal in <italic>H1047R</italic> mutants, with ectopic Ctip2/BrdU double-labeled cells in the upper and lower CP and white matter, instead of mid CP (<xref ref-type="fig" rid="fig6">Figure 6f</xref>). In <italic>E545K</italic> mutants, fewer Ctip2<sup>+</sup> cells were positioned in the mid CP (<xref ref-type="fig" rid="fig6">Figure 6n</xref>), although the phenotype was much less severe.<fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.12703.018</object-id><label>Figure 6.</label><caption><title>Birthdating assays demonstrate defects in laminar distribution.</title><p>(<bold>a</bold>) Experimental outline of birthdating assays: BrdU was injected at E12.5 and E16.5 and analyzed at P0 (B12.5;P0 and B16.5;P0). Total number of BrdU<sup>+</sup> cells at P0 generated at E12.5 and E16.5 (<bold>b,j</bold>), and total number of Ctip2<sup>+</sup> cells (layer V neurons; d,l) were not significantly different between respective controls and mutants, for both <italic>H1047R</italic> and <italic>E545K</italic> lines. (<bold>c</bold>) Distribution of BrdU<sup>+</sup> cells in the neocortex was significantly different between control and <italic>hGFAP-cre;H1047R</italic> mutant for both early and late assays, with more cells residing in the lower cortical plate and white matter instead of mid and upper zones of the cortical plate. (<bold>e,m</bold>) Total number of layer V neurons in both <italic>H1047R</italic> and <italic>E545K</italic> mutants, born at E12.5 and at E16.5, did not significantly differ from the respective controls; but showed significant difference in their zonal distribution with Ctip2<sup>+</sup>BrdU<sup>+</sup> cells predominating the lower cortical plate in both the mutants (<bold>f,n</bold>). Total number of Cux1<sup>+ </sup>neurons (layers II/III neurons; g,o) was significantly higher in both the mutants compared with the respective controls. The colocalization of Cux1 and BrdU was not significantly different in the <italic>H1047R</italic> mutant and control for both ages (h); but number of Cux1<sup>+</sup> cells born at E16.5 was significantly higher in <italic>E545K</italic> mutant than in the control (<bold>p</bold>). (<bold>i,q</bold>) Zonal distribution of Cux1<sup>+</sup> cells was significantly different between controls and mutants, with more Cux1<sup>+</sup> cells residing at the lower portion of the P0 cortical plate. The <italic>H1047R</italic> mutant phenotype is more extreme than the <italic>E545K</italic> mutant. Data are represented as mean ± SEM. *p&lt;0.05; **p&lt;0.001; ***p&lt;0.0001.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.018">http://dx.doi.org/10.7554/eLife.12703.018</ext-link></p></caption><graphic xlink:href="elife-12703-fig6-v2.tif"/></fig></p><p>Upper layer (Cux1<sup>+</sup>) neuronal numbers and distributions were significantly different in both <italic>H1047R</italic> and <italic>E545K</italic> mutants, compared to their respective controls (<xref ref-type="fig" rid="fig6">Figure 6g,o</xref>). In <italic>E545K</italic> mutants, the increase in total Cux1<sup>+</sup> cell numbers in the <italic>E545K</italic> mutant corresponded to increased Cux1/BrdU double-labeled cells, born at E16.5 (<xref ref-type="fig" rid="fig6">Figure 6p</xref>). However, no such correlation was observed in E12.5 or E16.5-born Cux1<sup>+</sup> cells in the <italic>H1047R</italic> mutant (<xref ref-type="fig" rid="fig6">Figure 6h</xref>). These extra cells were therefore likely born between E16.5 and P0. The distribution of Cux1<sup>+</sup> cells was disrupted in both mutants, with the <italic>H1047R</italic> mutant displaying the more severe phenotype (<xref ref-type="fig" rid="fig6">Figure 6i,q</xref>). Together, these data indicate that cell fates are largely correctly specified in both <italic>Pik3ca</italic> mutants and that cortical dysplasia is more likely caused by aberrant neuronal migration.</p></sec><sec id="s2-4"><title><italic>Pik3ca</italic> mutations cause white matter dysplasia</title><p>In P3 <italic>hGFAP-cre;H1047R</italic> mutants, although the cortical plate itself was not dramatically thicker than controls, the underlying cortical white matter was much thicker (<xref ref-type="fig" rid="fig4">Figure 4j,k</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4—figure suplement 2e,f</xref>). This was less pronounced but readily discernible in P3 <italic>Nestin-cre;E545K</italic> mutants (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2c,d</xref>). In P3 <italic>H1047R mutants</italic>, there was complete absence of corpus callosum, although hippocampal and anterior commissures were present (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a-d</xref>). In contrast, all major tracts were present in P3 <italic>E545K</italic> mutants (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 2</xref>). These data are consistent with the wide spectrum of white matter dysplasia reported in MEG and SEGCD patients (<xref ref-type="bibr" rid="bib15">Conway et al., 2007</xref>; <xref ref-type="bibr" rid="bib1">Adamsbaum et al., 1998</xref>; <xref ref-type="bibr" rid="bib18">De Rosa et al., 1992</xref>; <xref ref-type="bibr" rid="bib33">Jansen et al., 2015</xref>). Moreover, increased number of Olig2-positive cells was observed in the white matter area of both <italic>H1047R</italic> and <italic>E545K</italic> mutants (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Although astrocytosis is observed when mTOR signaling is activated by TSC mutations in humans and mice (<xref ref-type="bibr" rid="bib63">Sosunov et al., 2008</xref>; <xref ref-type="bibr" rid="bib71">Zeng et al., 2008</xref>), it is not a feature of PIK3CA-pathology in our mouse models (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3a-d</xref>).</p></sec><sec id="s2-5"><title>Both megalecephalic and normocephalic <italic>E545K</italic> mutant mice are epileptic</title><p>Epilepsy is one of the most important clinical features of SEGCD (<xref ref-type="bibr" rid="bib5">Bast et al., 2006</xref>; <xref ref-type="bibr" rid="bib21">Fauser et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Fauser, 2006</xref>; <xref ref-type="bibr" rid="bib2">Arai et al., 2012</xref>). Since most of the <italic>H1047R</italic> mutants were not viable post-weaning, we assessed <italic>Nestin-cre;E545K</italic> (megalencephalic) and <italic>Nestin-creER;E545K</italic> (normocephalic) adults for epilepsy phenotypes. Baseline sleep EEG recordings in both animal models revealed epileptiform activity including sets of spikes/polyspikes, and regional and generalized spike and wave discharges during non-rapid eye movement (NREM) sleep (<xref ref-type="fig" rid="fig7">Figure 7b,c</xref>). We also conducted additional 2 hr of continuous EEG recording immediately after 5 hr of total sleep deprivation of the <italic>Nestin-creER;E545K</italic> mice. Sleep deprivation is commonly implemented during epilepsy diagnostic studies in mice and humans and increases the sensitivity and specificity of EEG diagnosis for epilepsy (<xref ref-type="bibr" rid="bib18">De Rosa et al., 1992</xref>; <xref ref-type="bibr" rid="bib27">Giorgi et al., 2013</xref>; <xref ref-type="bibr" rid="bib9">Binnie and Prior, 1994</xref>; <xref ref-type="bibr" rid="bib35">Kalume et al., 2015</xref>). The frequency of epileptiform interictal activity was increased in post sleep deprivation EEG recordings, and clinically relevant spontaneous seizures including myoclonic (MC) seizures, frequent isolated spikes, and train of spikes, were observed in the <italic>Nestin-creER;E545K</italic> mice (<xref ref-type="fig" rid="fig7">Figure 7d,e</xref>).<fig-group><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.12703.019</object-id><label>Figure 7.</label><caption><title>PI3K activity acutely modulates epileptic seizures.</title><p>(<bold>a</bold>) Schematic shows electrode placement for EEG recordings. LF=Left Frontal, LP= Left Posterior, RF=Right Frontal, RP= Right Posterior. Only 2 electrodes were placed in P35 <italic>Nestin-cre;E545K</italic>. (<bold>b</bold>) EEG-EMG tracings of <italic>Nestin-cre;E545K</italic> mutant showed bilateral spikes/polyspikes, myoclonic (MC) seizures, fast and slow wave discharges, not associated with movement on video or EMG activity. (<bold>c</bold>) Generalized (<bold>G</bold>) and regional (<bold>R</bold>) spike and wave discharges were observed in <italic>Nestin-creER;E545K</italic> mice. Scale: 1s,1mV. (d,e) Sleep deprivation (SD) enhances epileptiform EEG activity in <italic>Nestin-creER;E545K</italic> mutant. EEG tracings of a <italic>Nestin-creER;E545K</italic> mutant mouse after 5 hr of normal sleep (Pre SD) and after 5 hr of total sleep deprivation (Post SD) in the same mouse (<bold>d</bold>), the mutant showing myoclonic (MC) seizures and isolated regional spikes (<bold>R</bold>). Power spectrum analysis, representing the frequency distribution for EEG activity over time, also displayed increased activity of the mutant post SD (<bold>e</bold>). (<bold>f</bold>) Bar chart showing average number of seizures (SZ) in PTZ-induced P35 <italic>Nestin-cre;E545K</italic> and control over time. (<bold>g</bold>) Experimental outline for BKM120-PTZ test. (<bold>h</bold>) Total number of seizures was significantly higher in P35 mutants than controls. Acute administration of BKM120 reduced number of seizures in mutants. (<bold>i</bold>) Duration of sustained generalized tonic-clonic seizure state (Racine 5), normalized to the total time of test, was significantly longer in P35 <italic>Nestin-cre;E545K</italic> mutants than controls. BKM120 significantly reduced the duration. Data are represented as mean ± SEM. *p&lt;0.05; **p&lt;0.0001. See also <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.019">http://dx.doi.org/10.7554/eLife.12703.019</ext-link></p></caption><graphic xlink:href="elife-12703-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.12703.020</object-id><label>Figure 7—figure supplement 1.</label><caption><title>Seizure activity of <italic>E545K</italic> mutants at old age.</title><p>(<bold>a</bold>) Experimental outline for ~P180 constitutive (<italic>Nestin-cre;E545K)</italic> mice: Seizures were induced in mice by administering PTZ subcutaneously and then video recorded for 30 min. (<bold>b,c</bold>) Total number of seizures was not significantly different in P180 <italic>Nestin-cre;E545K</italic> while duration spent by these mutants in severe seizure attacks (Racine 5), measured as a percentage of the total time of recording, was significantly longer compared to respective controls. (<bold>d</bold>) Table showing percentage of generalized tonic clonic seizures (GTC SZ) and mean latency (in mins) across different genotypes and age groups. (<bold>e,f</bold>) In ~P35 <italic>Nestin-creER;E545K</italic> mutants, total seizure number was higher while duration spent in Racine 5, measured as a percentage of the total time of recording, was the same as respective controls. (<bold>g,h</bold>) In ~P180 <italic>Nestin-creER;E545K</italic> mutants, total seizure number was comparable to the controls but the duration in Racine 5 was different compared to respective controls. *p&lt;0.01; **p&lt;0.001.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.020">http://dx.doi.org/10.7554/eLife.12703.020</ext-link></p></caption><graphic xlink:href="elife-12703-fig7-figsupp1-v2.tif"/></fig></fig-group></p><p>When challenged with the chemoconvulsant pentylenetetrazol (PTZ), a GABA-A receptor antagonist (<xref ref-type="bibr" rid="bib47">Macdonald and Barker, 1978</xref>), both the megalencephalic and normocephalic <italic>E545K</italic> mouse models exhibited lower seizure thresholds compared to controls at both P35 and P180 (<xref ref-type="fig" rid="fig7">Figure 7f–i</xref>; <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1d</xref>). In the 30 min post PTZ injection, both models showed shorter latencies to first generalized tonic clonic (GTC) seizures, more myoclonic seizures, and a prolonged seizure load.</p><p>We conclude that <italic>Pik3ca</italic> overactivation is sufficient to cause epilepsy. Further our data indicate that <italic>Pik3ca</italic>-related epilepsy is dissociable from brain overgrowth and cortical dysplasia.</p></sec><sec id="s2-6"><title>Acute inhibition of Pik3ca activity suppresses epilepsy, rapidly altering cell signaling</title><p>BKM120, a 2,6-dimorpholino pyrimidine derivative, is an orally available pan-Class I PI3K inhibitor currently in clinical trials for solid tumors (<xref ref-type="bibr" rid="bib48">Maira et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Bendell et al., 2012</xref>; <xref ref-type="bibr" rid="bib11">Brachmann et al., 2012</xref>) and may represent a novel therapeutic agent for <italic>PIK3CA</italic>-related epilepsy. Preclinical studies show that BKM120 maximally inhibits downstream phosphorylation of Akt, 1hr post-administration (<xref ref-type="bibr" rid="bib48">Maira et al., 2012</xref>). To test its anti-seizure effects in our adult <italic>Pik3ca<sup>E545K</sup></italic> gain-of-function megalencephalic and normocephalic models, we administered 50 mg/kg BKM120 (<xref ref-type="bibr" rid="bib48">Maira et al., 2012</xref>) by oral gavage 1hr prior to PTZ-challenge at ~P35. BKM120 increased the seizure threshold of control animals. More importantly, despite the presence of megalencephaly and considerable cortical dysplasia in P35 <italic>Nestin-cre;E545K</italic> megencephalic animals, BKM120 dramatically decreased the seizure number and duration to untreated control levels and marginally increased seizure latency in the mutant mice (<xref ref-type="fig" rid="fig7">Figure 7h,i</xref>; <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1d</xref>). These data powerfully demonstrate that dynamic Pik3ca-dependent processes, independent of cortical and cellular dysplasia, cause <italic>Pik3ca</italic>-related epilepsy and they are highly amenable to therapeutic intervention.</p><p>To begin to dissect the cell signaling mechanisms underlying Pik3ca-driven epilepsy, we conducted reverse phase protein array (RPPA) analysis to measure protein levels of a comprehensive panel of cell signaling molecules (<xref ref-type="bibr" rid="bib67">Tibes et al., 2006</xref>). We assessed subdissected cortical and hippocampal tissue from untreated (-) and PTZ, BKM120 and BKM120 PTZ treated adult control and <italic>Nestin-cre;E545K</italic> mutants (<xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). As expected, untreated <italic>Nestin-cre;E545K</italic> mutants exhibited significant elevations of phospho (p)S473-Akt and pT346-NDRG1, consistent with PI3K pathway activation. Notably, baseline pS473-Akt levels in the <italic>Nestin-cre;E545K</italic> hippocampus were prominently higher than the cortical levels. In both <italic>E545K</italic> mutant and control brain tissues, PTZ treatment alone increased the levels of pAkt, especially pS473-Akt, of pS6 (pS235/S236, pS240/244), pT346-NDRG1 and pS2448-mTOR. As expected, acute BKM120 treatment alone reduced phosphorylation of multiple PI3K pathway members, including AKT, S6, NDRG1, GSK3 and 4EBP1. Most remarkably, BKM120 also inhibited the increased phosphorylation levels induced by PTZ, notably returning mutant hippocampal pS473-AKT levels to baseline untreated control levels.<fig-group><fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.12703.021</object-id><label>Figure 8.</label><caption><title>BKM120 acutely alter PI3K pathway protein profile.</title><p>(<bold>a–g</bold>) Graphs show differential protein levels in P35 <italic>Nestin-cre;E545K</italic> mutant and control brains due to different treatments: untreated (-); BKM120; PTZ; BKM120+PTZ. Data are represented as mean ± SEM. *p&lt;0.05. Inset shows simplified PI3K pathway; BKM120 significantly regulated the highlighted molecules. See also <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.021">http://dx.doi.org/10.7554/eLife.12703.021</ext-link></p></caption><graphic xlink:href="elife-12703-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.12703.022</object-id><label>Figure 8—figure supplement 1.</label><caption><title>RPPA analysis graphs.</title><p>Protein profile of cortical and hippocampal samples from untreated and treated P35 control and <italic>Nestin-cre;E545K</italic> mutant. Graphs show differential protein levels due to PTZ and BKM120 treatments on control and <italic>Nestin-cre;E545K</italic> mutant.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.022">http://dx.doi.org/10.7554/eLife.12703.022</ext-link></p></caption><graphic xlink:href="elife-12703-fig8-figsupp1-v2.tif"/></fig></fig-group></p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title><italic>PIK3CA</italic>-related disorders (PROS) in humans</title><p>Activating <italic>PIK3CA</italic> mutations have been associated with many human overgrowth disorders categorized based on severity and distribution of the mutation. Involvement of multiple tissues results in CLOVES or Klippel-Trenaunay syndrome with highly mosaic mutation levels (0.8–32%) in affected tissues (<xref ref-type="bibr" rid="bib46">Luks et al., 2015</xref>; <xref ref-type="bibr" rid="bib40">Kurek et al., 2012</xref>). Involvement of single tissue or body segment results in epidermal nevi, lymphatic malformations or other localized phenotypes with usually no mutations detected in unaffected tissues (<xref ref-type="bibr" rid="bib37">Keppler-Noreuil et al., 2014</xref>; <xref ref-type="bibr" rid="bib46">Luks et al., 2015</xref>; <xref ref-type="bibr" rid="bib40">Kurek et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Osborn et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Groesser et al., 2012</xref>; <xref ref-type="bibr" rid="bib44">Lindhurst et al., 2012</xref>; <xref ref-type="bibr" rid="bib30">Hafner et al., 2007</xref>; <xref ref-type="bibr" rid="bib56">Rios et al., 2013</xref>; <xref ref-type="bibr" rid="bib14">Cohen et al., 2014</xref>). Too few patients and insufficient quantitative data have been reported to observe allele-specific differences.</p><p>In the brain, mosaic hotspot mutations result in SEGCD, classified as dysplastic MEG, HMEG or FCD2a based on extent of lesion (<xref ref-type="bibr" rid="bib33">Jansen et al., 2015</xref>). <italic>PIK3CA</italic> mutations were detected in 9/73 patients with HMEG and 1/33 with FCD2 (<xref ref-type="bibr" rid="bib42">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="bib17">D'Gama et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Jansen et al., 2015</xref>). These overlapping SEGCD are associated with severe and usually intractable epilepsy (<xref ref-type="bibr" rid="bib5">Bast et al., 2006</xref>; <xref ref-type="bibr" rid="bib21">Fauser et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Fauser, 2006</xref>; <xref ref-type="bibr" rid="bib54">Pasquier et al., 2002</xref>; <xref ref-type="bibr" rid="bib60">Russo et al., 2003</xref>; <xref ref-type="bibr" rid="bib65">Tassi, 2002</xref>; <xref ref-type="bibr" rid="bib19">Devlin, 2003</xref>; <xref ref-type="bibr" rid="bib10">Blümcke et al., 2011</xref>). ~20 other <italic>PIK3CA</italic> mutant alleles have been seen in MCAP, characterized by MEG or MEG-PMG, hydrocephalus and less severe epilepsy (<xref ref-type="bibr" rid="bib29">Gymnopoulos et al., 2007</xref>; <xref ref-type="bibr" rid="bib51">Mirzaa et al., 2012</xref>; <xref ref-type="bibr" rid="bib57">Rivière et al., 2012</xref>; <xref ref-type="bibr" rid="bib66">Tatton-Brown and Weksberg, 2013</xref>).</p><p>We activated the two most common hotspot mutations, <italic>E545K</italic> and <italic>H1047R</italic>, in mouse brain at different developmental timepoints to generate the first models of human <italic>PIK3CA</italic>-related SEGCD. Our mouse models faithfully recapitulated the most important <italic>PIK3CA</italic>-related phenotypes of MEG, hydrocephalus, cortical and white matter dysplasia, and epilepsy (<xref ref-type="table" rid="tbl1">Table 1</xref>).<table-wrap id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.12703.023</object-id><label>Table 1.</label><caption><p>Table displays comparison of the key features across different <italic>Pik3ca</italic> genetic models used in this study.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.023">http://dx.doi.org/10.7554/eLife.12703.023</ext-link></p></caption><table frame="hsides" rules="groups"><tbody><tr><td style="background: #999999;"><p><bold>Mutant allele</bold></p> </td><td align="center" colspan="2" style="background: #FF6600; color: #FFFFFF;"><p><bold>H1047R</bold></p> </td><td align="center" colspan="3" style="background: #000080; color: #FFFFFF;"><p><bold>E545K</bold></p> </td></tr><tr><td style="background: #999999;"><p><bold>Cre driver</bold></p> </td><td align="center" style="background: #FFCC00;"><p><bold>hGFAP-cre</bold>(dox from E0.5)</p></td><td align="center" style="background: #FFCC99;"><p><bold>hGFAP-cre</bold>(dox from P1)</p></td><td align="center" style="background: #3366FF;"><p><bold>Nestin-cre</bold></p> </td><td align="center" style="background: #00CCFF;"><p><bold>hGFAP-cre</bold></p> </td><td align="center" style="background: #99CCFF;"><p><bold>Nestin-creERT2</bold>(tamoxifen @P0/P1)</p></td></tr><tr><td style="background: #999999;"><p><bold>GoF expression onset</bold></p> </td><td align="center" style="background: #FFCC00;"><p>Late embryonic</p></td><td align="center" style="background: #FFCC99;"><p>Neonatal</p></td><td align="center" style="background: #3366FF;"><p>Early embryonic</p></td><td align="center" style="background: #00CCFF;"><p>Late embryonic</p></td><td align="center" style="background: #99CCFF;"><p>Neonatal</p></td></tr><tr><td style="background: #999999;"><p><bold>Viability</bold></p> </td><td align="center" style="background: #FFCC00;"><p>Lethal by weaning age</p></td><td align="center" style="background: #FFCC99;"><p>Viable</p></td><td align="center" style="background: #3366FF;"><p>Viable</p></td><td align="center" style="background: #00CCFF;"><p>Viable</p></td><td align="center" style="background: #99CCFF;"><p>Viable</p></td></tr><tr><td style="background: #999999;"><p><bold>Megalencephaly</bold></p> </td><td align="center" style="background: #FFCC00;"><p>✓</p></td><td align="center" style="background: #FFCC99;"><p>X</p></td><td align="center" style="background: #3366FF;"><p>✓</p></td><td align="center" style="background: #00CCFF;"><p>✓ (intermediate)</p></td><td align="center" style="background: #99CCFF;"><p>X</p></td></tr><tr><td style="background: #999999;"><p><bold>Hydrocephalus</bold></p> </td><td align="center" style="background: #FFCC00;">✓</td><td align="center" style="background: #FFCC99;"><p>X</p></td><td align="center" style="background: #3366FF;"><p>X</p></td><td align="center" style="background: #00CCFF;"><p>X</p></td><td align="center" style="background: #99CCFF;"><p>X</p></td></tr><tr><td style="background: #999999;"><p><bold>Increased cell size</bold></p> </td><td align="center" style="background: #FFCC00;"><p>✓</p></td><td align="center" style="background: #FFCC99;"><p>Not tested</p></td><td align="center" style="background: #3366FF;">✓</td><td align="center" style="background: #00CCFF;"><p>X</p></td><td align="center" style="background: #99CCFF;"><p>X</p></td></tr><tr><td style="background: #999999;"><p><bold>Cortical dysplasia</bold></p> </td><td align="center" style="background: #FFCC00;"><p>✓</p></td><td align="center" style="background: #FFCC99;"><p>X</p></td><td align="center" style="background: #3366FF;">✓</td><td align="center" style="background: #00CCFF;"><p>X</p></td><td align="center" style="background: #99CCFF;"><p>X</p></td></tr><tr><td style="background: #999999;"><p><bold>White matter dysplasia</bold></p> </td><td align="center" style="background: #FFCC00;"><p>✓</p></td><td align="center" style="background: #FFCC99;"><p>X</p></td><td align="center" style="background: #3366FF;">✓</td><td align="center" style="background: #00CCFF;"><p>✓ (data not shown)</p></td><td align="center" style="background: #99CCFF;"><p>X</p></td></tr><tr><td style="background: #999999;"><p><bold>Epilepsy</bold></p> </td><td align="center" style="background: #FFCC00;"><p>Not tested</p></td><td align="center" style="background: #FFCC99;"><p>Not tested</p></td><td align="center" style="background: #3366FF;">✓</td><td align="center" style="background: #00CCFF;"><p>Not tested</p></td><td align="center" style="background: #99CCFF;"><p>✓</p></td></tr></tbody></table></table-wrap></p></sec><sec id="s3-2"><title>Differential activating mechanisms underlie <italic>Pik3ca</italic> allele-specific brain phenotypes</title><p>Data from cancer biology suggests that <italic>H1047R</italic> mutation is more severe than <italic>E545K</italic> mutation. For example, <italic>E545K</italic> mutation accounts for 1932/7548 (26%) and <italic>H1047R</italic> for 2898/7548 (38%) of <italic>PIK3CA</italic>-coding mutations detected in the COSMIC database of cancer mutations (<underline><ext-link ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk/cancergenome/projects/cosmic">http://cancer.sanger.ac.uk/cancergenome/projects/cosmic</ext-link></underline>).</p><p>We found that <italic>H1047R</italic> and <italic>E545K</italic> mutations caused distinct phenotypes in mice, <italic>H1047R</italic> being more severe than <italic>E545K. hGFAP-cre;H1047R</italic> mutants had severe hydrocephalus and died pre-weaning. In contrast all mice with the <italic>E545K</italic> allele survived through adulthood without hydrocephalus. Developmental analyses of <italic>hGFAP-cre;H1047R</italic> and <italic>Nestin-cre;E545K</italic> embryos revealed common mechanisms, such as larger neurons and lower cell densities, contributing to enlarged brain size, with differences more significant in <italic>H1047R</italic> mutants. <italic>E545K</italic> mutation also elevated cortical proliferation and cell cycle exit during late neurogenesis. We do not believe that overexpression of the transgenic <italic>H1047R</italic> allele versus the knock-in design of the <italic>E545K</italic> allele underlies the phenotypic differences. The PI3K enzyme is made of p110 (encoded by <italic>Pik3ca</italic>) and p85 subunits. p110 stability is entirely dependent on levels of p85 (<xref ref-type="bibr" rid="bib26">Geering et al., 2007</xref>; <xref ref-type="bibr" rid="bib25">Fruman et al., 2000</xref>; <xref ref-type="bibr" rid="bib69">Yu et al., 1998</xref>) and we have not altered p85. Rather, the phenotypic differences more likely reflect distinct allele-specific overactivation of PI3K signaling. The <italic>H1047R</italic> mutation increases the level and duration of response to extracellular ligand, while <italic>E545K</italic> alters the helical domain resulting in constitutive low level signaling with a blunted response to extracellular ligands (<xref ref-type="bibr" rid="bib50">Miled et al., 2007</xref>; <xref ref-type="bibr" rid="bib73">Zhao and Vogt, 2008</xref>).</p><p>These differences likely reflect distinct mechanisms differentially altering PI3K signaling. Whereas <italic>H1047R</italic> mutation increases the level and duration of response to extracellular ligand, <italic>E545K</italic> alters the helical domain resulting in constitutive low level signaling with a blunted response to extracellular ligands (<xref ref-type="bibr" rid="bib50">Miled et al., 2007</xref>; <xref ref-type="bibr" rid="bib73">Zhao and Vogt, 2008</xref>).</p></sec><sec id="s3-3"><title>Effect of <italic>Pik3ca</italic> overactivation on brain and cell size is temporally regulated</title><p>By activating the <italic>E545K</italic> mutation in progressively limited progenitor pools, we decreased the size of brain and cells in a graduated fashion. Postnatal <italic>E545K</italic> activation had no impact on cell/brain size. We conclude that the <italic>PIK3CA</italic>-related brain overgrowth must arise from mosaic mutations in embryonic neural progenitors.</p><p>Although neuronal size was enlarged in both <italic>hGFAP-cre;H1047R</italic> and <italic>Nestin-cre;E545K</italic> mutants, it was less than that observed in <italic>Pten null</italic> mice or in cultured hippocampal neurons constitutively overexpressing <italic>Akt </italic>(<xref ref-type="bibr" rid="bib39">Kumar, 2005</xref>; <xref ref-type="bibr" rid="bib41">Kwon et al., 2001</xref>). Multiple models of <italic>Pten</italic> deletion cause progressive increases in postnatal neuronal size and increased brain size without continued proliferation (<xref ref-type="bibr" rid="bib41">Kwon et al., 2001</xref>; <xref ref-type="bibr" rid="bib24">Fraser, 2004</xref>; <xref ref-type="bibr" rid="bib23">Fraser et al., 2008</xref>; <xref ref-type="bibr" rid="bib3">Backman et al., 2001</xref>). Our <italic>Nestin-cre;E545K</italic> mutants had enlarged brain size evident at birth, without progressive increases in postnatal cell size. This is congruent with the analysis of resected human brain tissue from SEGCD patients. Mild cellular enlargement was observed with <italic>PIK3CA</italic> mutations in contrast to marked enlargement with <italic>PTEN</italic> or <italic>AKT3</italic> mutations (<xref ref-type="bibr" rid="bib33">Jansen et al., 2015</xref>).</p></sec><sec id="s3-4"><title>Aberrant neuronal migration is a major contributor to Pik3ca-related cortical dysplasia</title><p>Brains of SEGCD patients show mild to moderate migration defects in early-born cortical neurons and more severe defects in late-born neurons (<xref ref-type="bibr" rid="bib2">Arai et al., 2012</xref>; <xref ref-type="bibr" rid="bib59">Rossini et al., 2014</xref>). Similarly, embryonic activation of <italic>H1047R</italic> and <italic>E545K</italic> in mice caused abnormal neocortical lamination, with late-migrating Cux1-positive neurons severely affected in both the mutants. Birthdating studies support the conclusion that Pik3ca activation does not alter cell fate and that cortical dysplasia is predominantly a result of aberrant migration. The severity of dyslamination in <italic>H1047R</italic> mutants likely reflects the dysplastic Reelin-positive Cajal-Retzius cells. However the Reelin-positive layer remained well defined in both mutants. This is in contrast to the ectopic Reelin expression in neurons expressing high levels of overactive pAKT introduced by electroporation into embryonic mouse cortex (<xref ref-type="bibr" rid="bib4">Baek et al., 2015</xref>). In human SEGCD, late migrating neurons often fail to migrate to the upper layers (<xref ref-type="bibr" rid="bib2">Arai et al., 2012</xref>), a phenotype more severe than seen in any of our mouse models. However, NeuN immunohistochemistry in <italic>H1047R</italic> mutants confirmed the presence of ectopic neurons in the subcortical white matter, as seen in human SEGCD brain (<xref ref-type="bibr" rid="bib2">Arai et al., 2012</xref>; <xref ref-type="bibr" rid="bib61">Salamon, 2006</xref>). Human MEG is associated with a wide range of white matter dysplasia ranging from agenesis of corpus callosum to thickening of subcortical axon bundles (<xref ref-type="bibr" rid="bib15">Conway et al., 2007</xref>; <xref ref-type="bibr" rid="bib1">Adamsbaum et al., 1998</xref>; <xref ref-type="bibr" rid="bib18">De Rosa et al., 1992</xref>; <xref ref-type="bibr" rid="bib33">Jansen et al., 2015</xref>; <xref ref-type="bibr" rid="bib61">Salamon, 2006</xref>). These features were also faithfully recapitulated in our mouse models.</p></sec><sec id="s3-5"><title><italic>Pik3ca</italic>-related epilepsy is an active Pik3ca-dependent process dissociable from dysmorphology</title><p>Both adult megalencephaic <italic>Nestin-cre;E545K</italic> and normocephalic <italic>Nestin-creER;E545K</italic> mice exhibited spontaneous seizures as well as lowered seizure thresholds upon PTZ-seizure induction. Although cortical dysplasia resulted from embryonic activation of <italic>Pik3ca</italic> in <italic>Nestin-cre;E545K</italic> mice, postnatal activation of <italic>Nestin-creER;E545K</italic> did not cause increased cell size or megalencephaly or altered cortical lamination. Thus Pik3ca-dependent epilepsy is independent of dysmorphology. Further, inhibitory interneurons were not grossly perturbed in <italic>Nestin-creER;E545K</italic> mice (data not shown). This is congruent with the fact that these interneurons are born at embryonic stages and their migration is almost complete before birth (<xref ref-type="bibr" rid="bib6">Batista‐Brito and Fishell, 2009</xref>). Therefore altered interneuron development in <italic>Nestin-cre;E545K</italic> may contribute to epilepsy, aberrant interneuron development cannot represent a common mechanism for epilepsy in both models. The observation that acute BKM120 treatment is sufficient to inhibit PTZ-induced seizures even in adult megalencephalic mice supports the argument that the epileptic seizures are independent of dysplasia since the latter is not reversed over the short course of treatment. This is an important finding since a large portion of FCD patients who do not show detectable dysplasia suffer from intractable epilepsy (<xref ref-type="bibr" rid="bib8">Bernasconi et al., 2011</xref>).</p><p>Proteomic analyses of cell signaling networks in megalencephalic cortical and hippocampal tissue at baseline and treated with PTZ and/or BKM120 provide insight into the mechanism of Pik3ca-dependent epilepsy. <italic>Nestin-cre;E545K</italic> mutants had elevated PI3K signaling with a more robust upregulation of mTOR-dependent pS473-Akt than the direct PDK1-dependent pT308-Akt, similar to the recent findings in human brain samples with <italic>PIK3CA</italic> mutations (<xref ref-type="bibr" rid="bib33">Jansen et al., 2015</xref>). The modest changes in signaling compared to controls is congruent with previous studies which demonstrated only modest changes in the steady-state levels of PI3K signaling in breast cancer cells with <italic>PIK3CA</italic> mutations (<xref ref-type="bibr" rid="bib64">Stemke-Hale et al., 2008</xref>). Higher signaling levels in hippocampus versus cortex suggest a more prominent role of hippocampus in the seizure phenotype. PTZ administration alone in both controls and megalencephalic <italic>Nestin-cre;E545K</italic> mutants caused upregulation of many core components of PI3K-AKT pathway, including pAkt, pS6 and pNDRG1. This is congruent with a report showing PTZ-induced seizures in rats upregulated PI3K-AKT-mTOR pathway (<xref ref-type="bibr" rid="bib72">Zhang and Wong, 2012</xref>) and suggests that elevated baseline PI3K signaling levels are epileptogenic.</p><p>Indeed, there is extensive human and mouse evidence that elevated mTOR signaling is epileptogenic although the mechanisms for the epilepsy are incompletely understood. A number of mechanisms including altered development, cell size, growth, proliferation and circuitry have been reported (<xref ref-type="bibr" rid="bib68">Wong and Crino, 2012</xref>). Most remarkably however, our acute BKM120 administration data clearly demonstrates that histopathological mechanisms are not the primary epilepsy drivers. Acute 1 hr of BKM120 administration was sufficient to completely inhibit the increased phosphorylation levels induced by PTZ, notably returning mutant hippocampal mTOR-dependent pS473-AKT levels to baseline untreated control levels. This was sufficient to normalize the PTZ-seizure induction threshold, despite continued dysplasia in <italic>Nestin-cre;E545K</italic> mutants. We conclude that elevated PI3K signaling is itself actively epileptogenic, independent of underlying developmental pathology.</p></sec><sec id="s3-6"><title>Changing the face of intractable pediatric epilepsy</title><p>The discovery that <italic>Pik3ca</italic>-related epilepsy is independent of dysplasia and susceptible to acute modulation is a major and paradigm shifting finding. Since PIK3CA resides at the top of the PI3K-AKT pathway, our mouse models represent surrogates for the entire group of patients with segmental brain overgrowth, including patients with somatic mosaic mTOR and AKT3 mutations (<xref ref-type="bibr" rid="bib37">Keppler-Noreuil et al., 2014</xref>; <xref ref-type="bibr" rid="bib42">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="bib17">D'Gama et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Conway et al., 2007</xref>; <xref ref-type="bibr" rid="bib33">Jansen et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Mirzaa et al., 2012</xref>). SEGCD is associated with early onset, severe and frequently intractable epilepsy that responds poorly to standard seizure medications (<xref ref-type="bibr" rid="bib5">Bast et al., 2006</xref>; <xref ref-type="bibr" rid="bib21">Fauser et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Fauser, 2006</xref>; <xref ref-type="bibr" rid="bib54">Pasquier et al., 2002</xref>; <xref ref-type="bibr" rid="bib60">Russo et al., 2003</xref>; <xref ref-type="bibr" rid="bib65">Tassi, 2002</xref>). Epilepsy surgery has been comparatively more successful (73%) in combating seizures in the same children (<xref ref-type="bibr" rid="bib21">Fauser et al., 2015</xref>). A drug-based therapy however, would clearly be preferable. mTOR inhibition with rapamycin has shown therapeutic promise in FCD patients and animals models (<xref ref-type="bibr" rid="bib4">Baek et al., 2015</xref>; <xref ref-type="bibr" rid="bib16">Curatolo and Moavero, 2013</xref>; <xref ref-type="bibr" rid="bib43">Lim et al., 2015</xref>; <xref ref-type="bibr" rid="bib52">Moon et al., 2015</xref>); however, rapamycin treatments are not acute. Our data demonstrates that acute small molecule-based modulation of PI3K signaling, despite the presence of dysplasia, has dramatic therapeutic benefit. This suggests that PI3K inhibitors offer a promising new avenue for effective antiepileptic therapy for large cohorts intractable pediatric epilepsy patients.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice</title><p>The following mouse lines were used: <italic>Nestin-cre</italic> (Jackson Labs, Bar Harbor, Maine, USA; Stock #003771), <italic>Nestin-creERT2</italic> lines (Jackson Laboratory, Bar Harbor, Maine, USA, MGI:3641212 and line generated in SJB’s lab, <xref ref-type="bibr" rid="bib74">Zhu et al., 2012</xref>), human glial fibrillary acidic protein (<italic>hGFAP</italic>)-cre (Jackson Labs, Stock #004600), <italic>Pik3ca<sup>H1047R</sup></italic> transgenic (human <italic>H1047R</italic> transgene expression is under the control of a tetracycline-inducible promoter (TetO)) (<xref ref-type="bibr" rid="bib45">Liu et al., 2011</xref>), <italic>Rosa26-rtTA</italic> line (Jackson Labs, Stock #005670), <italic>Pik3ca<sup>E545K</sup></italic> knock-in (<xref ref-type="bibr" rid="bib58">Robinson et al., 2012</xref>), Ai-9 (Jackson Labs, Stock #007905), Ai-14 (Jackson Labs, Stock #007914), <italic>R26-LSL-EYFP</italic> (Jackson Labs, Stock #006148), <italic>Rosa26-LacZ</italic> (Jackson Labs, Stock #003474). We have designated the <italic>Pik3ca<sup>H1047R</sup></italic> and <italic>Pik3ca<sup>E545K</sup></italic> conditional mutant mice as <italic>H1047R</italic> and <italic>E545K</italic> mutants/lines throughout the manuscript.</p><p>All lines were maintained on a mixed genetic background, comprising of FVB, C57Bl6, 129 and CD1 strains. Noon of the day of vaginal plug was designated as embryonic day 0.5 (E0.5). The day of birth was designated as postnatal day 0 (P0). The <italic>H1047R</italic> and <italic>Rosa26-rtTA</italic> lines were intercrossed and female mice positive for both these alleles were crossed with <italic>hGFAP-cre;RosartTA;Pik3ca<sup>H1047R</sup></italic> males. To ensure that <italic>cre</italic> and <italic>Pik3ca<sup>H1047R</sup></italic> mutant transgene expression was correlated plugged females were treated with doxycycline (Sigma; 2 mg/ml) from E0.5 available <italic>ad libitum</italic> in drinking water. For the neonatal induction experiment, the pups were treated with doxycycline from P1. The <italic>E545K</italic> line was crossed to reporter lines to obtain <italic>E545K</italic> floxed allele and the reporter in the same mouse line. Tamoxifen (Sigma T5648) was dissolved at 37°C in corn oil (Sigma) at 5 mg/ml and was administered intraperitoneally to pups of the cross <italic>Nestin-creER</italic> X <italic>Pik3ca<sup>E545K </sup></italic>mice at a dose of 75 μg/g body weight, once a day at P0 and P1, to activate the <italic>E545K</italic> mutation postnatally. <italic>hGFAP–cre, Nestin–cre</italic> and <italic>Nestin–creERT2</italic> mice were genotyped by PCR using primers for the <italic>cre</italic> coding region, as previously described (<xref ref-type="bibr" rid="bib13">Chizhikov, 2006</xref>). Genotyping of other alleles were done according to the following references: <italic>H1047R</italic> and <italic>Rosa+/- </italic>(<xref ref-type="bibr" rid="bib45">Liu et al., 2011</xref>), <italic>E545Kfloxed/+ </italic>(<xref ref-type="bibr" rid="bib58">Robinson et al., 2012</xref>)<italic>, EYFP/+</italic> and <italic>Ai9/+ </italic> (<xref ref-type="bibr" rid="bib74">Zhu et al., 2012</xref>). All mouse procedures were approved by the Institutional Animal Care and Use Committees.</p></sec><sec id="s4-2"><title>Sample preparation and histochemical procedures</title><p>Embryos and postnatal pups were harvested in phosphate buffer saline (PBS); brains fixed in 4% paraformaldehyde (PFA) for 4 hr, equilibrated in 30% (wt/vol) sucrose made in PBS, and sectioned at 25 μm on a freezing microtome. Adult mice were perfused with 4% PFA, brains collected and fixed in 4% PFA overnight, sunk in 30% sucrose in PBS, embedded in optimum cutting temperature (OCT) compound and sectioned at 12 μm on a cryostat. Sections were then processed for Nissl, hematoxylin and eosin (H&amp;E) or immunohistochemical staining.</p><p><italic>Immunohistochemistry</italic>: Sections were washed thrice in PBS, boiled in 10 mM Sodium citrate solution for antigen retrieval, blocked in 5% serum in PBS with 0.1%Triton X-100 and then incubated overnight at 4°C with primary antibodies. The next day, sections were washed thrice in PBS, incubated with appropriate species-specific secondary antibodies conjugated with Alexa 488, 568, 594 or 647 fluorophores (Invitrogen) for 2 h at room temperature and then counterstained with DAPI to visualize nuclei. Sections were coverslipped using Fluorogel (EMS #17985) mounting medium. Immunostained sections were imaged in Zeiss LSM 710 Imager Z2 laser scanning confocal microscope using Zen 2009 software and later processed in ImageJ software (NIH, Bethesda, Maryland, USA). Primary antibodies used are: rat anti-BrdU (Abcam), mouse anti-BrdU (Roche), rabbit anti-Tbr1(EMD Millipore), mouse anti-Tbr2 (EMD Millipore), rat anti-Ctip2 (Abcam), rabbit anti-Cux1/CDP (Santa Cruz Biotechnology), rabbit anti-pS6 (Cell Signaling), mouse anti-NeuN (EMD Millipore), mouse anti-Reelin (EMD Millipore), rabbit anti-Laminin (Sigma), rabbit anti-Olig2 (EMD Millipore), mouse anti-Nestin (EMD Millipore), chicken anti-YFP (Abcam), rabbit anti-Ki67 (Vector Lab), mouse anti-S100 (Abcam).</p><p><italic>Nissl and H&amp;E staining</italic>: Sections were stained in 0.1% cresyl violet solution for 10 min, rinsed quickly in distilled water, dehydrated in 95% ethanol, and left in xylene before being coverslipped with Permount (Fischer Scientific). H&amp;E staining was performed by passing the sections through Harris modified Hematoxylin solution (Fisher Scientific) and EosinY (Sigma) and then dehydrating them in increasing grades of ethanol before dipping in xylene and coverslipping. Brightfield images were taken in Leica MZFLIII microscope using Leica DFC425 camera and LAS V3.8 software.</p></sec><sec id="s4-3"><title>BrdU incorporation experiments</title><p>Bromodeoxyuridine (BrdU; Life Technologies) was administered intraperitoneally (100 μg/g of body weight) to pregnant mice at E14.5/16.5 for 1 hr, at E15.5 for 1 day and at E12.5/E16.5 for proliferation assays, cell cycle exit and birthdating experiments respectively. S-phase labeling index (LI) was calculated by dividing total BrdU<sup>+</sup> cells by total number of DAPI<sup>+</sup> cells. Quit fraction was calculated by dividing BrdU<sup>+</sup>Ki67<sup>−</sup> cells by total number of BrdU<sup>+</sup> cells.</p></sec><sec id="s4-4"><title>β-Gal staining protocol </title><p>Brain sections were briefly fixed, washed in wash buffer at room temperature and then stained overnight at 37°C in the staining solution comprising of the X-gal substrate. The sections were then washed in wash buffer at room temperature and stored at 4°C.</p></sec><sec id="s4-5"><title>TUNEL staining</title><p>TUNEL staining was processed on E16.5 control and mutant sections using Roche In situ Cell Death Detection Kit, Fluorescein.</p></sec><sec id="s4-6"><title>Magnetic resonance imaging (MRI) for volumetric analysis</title><p>At least 5 mice of each genotype (age P40–60) were used for volumetric analyses. MRI study was performed using a 7 T Bruker ClinScan system (Bruker BioSpin MRI GmbH, Germany) equipped with 12S gradient coil. A 2-channel surface coil was used for MR imaging. Animals were anesthetized and maintained with 1.5% isoflurane during MRI sessions. Transverse T2-weighted turbo spin echo images were acquired for volume measurements (TR/TE = 3660/50 ms, FOV = 25 × 25 mm, matrix = 320 × 320, NEX = 1, thickness = 0.4 mm, scan time = 6.5 min). Total brain volumes were obtained by manually segmenting brain regions from olfactory bulbs to cerebellum, and computing volumes using OsiriX (Pixmeo, Switzerland). Each data point in the graph represents 1 mouse.</p></sec><sec id="s4-7"><title>Seizure experiments</title><p>Mice obtained from the following crosses were used for experiments at ~P35 (young age) and ~P180 (old age): <italic>Nestin-cre/+</italic> X <italic>Pik3ca<sup>E545K</sup>floxed/+</italic> and <italic>Nestin-creER/+</italic> X <italic>Pik3ca<sup>E545K</sup>floxed/+</italic>. At least 5 animals of each genotype were used per treatment experiment.</p><p><italic>Pentylenetetrazole (PTZ) seizure test.</italic> Mice were subcutaneously injected with PTZ (Sigma), a GABA (A) receptor-antagonist, at 40 mg/kg body weight and digital videos of the mice were recorded for 30 min post-PTZ injection. Principal behavior in each 10 second-bin of the recorded video was scored as 4 or 5 using the Racine scale of seizure severity (4, rearing with forelimb clonus; and 5, rearing and falling with forelimb clonus) (<xref ref-type="bibr" rid="bib36">Kalume, 2013</xref>; <xref ref-type="bibr" rid="bib55">Racine, 1972</xref>). <italic>Treatment trials.</italic> Pan-PI3K inhibitor BKM-120 (Novartis; 50 mg/kg body weight, dissolved in 0.5% Tween-80, 0.5% methylcellulose) or saline was administered by oral gavage to the mice 1hr before PTZ seizure test.</p><p><italic>Sleep deprivation (SD)</italic>. To permit control of circadian variations of sleep in these experiments, baseline (control) sleep data (Pre SD) were recorded from mice one day before they were submitted to total sleep deprivation. Mice were allowed to sleep normally for 5 continuous hours beginning at 8:00 AM, and then baseline sleep video-EEG recordings were obtained continuously in the 1 subsequent hour. On the following day, beginning at 8:00 AM, the same mice were kept awake for 5 consecutive hours by random gentle touches with a rotating light curtain attached to a motor mounted on the lid of the sleep deprivation chamber. The motor was in turn, connected to a computer via Power Lab (ADInstruments, Colorado Spring, CO). The random direction and speed of the motor rotation were custom-programmed in the stimulator panel dialog box of LabChart 8 Software (ADInstruments, Colorado Spring, CO). The specific parameters used are tabulated as <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1</xref>. Post sleep deprivation, mice were not disturbed and post SD recordings were obtained for 2hr.</p><p><italic>Video-electroencephalagraphy-electromyography (Video-EEG-EMG) recording.</italic> These experiments were performed as previously described (<xref ref-type="bibr" rid="bib36">Kalume, 2013</xref>). Briefly, mice underwent survival surgery to implant fine (diameter: 130 µm bare; 180 µm coated) silver wire EEG and EMG electrodes under isoflurane anesthesia. Four EEG electrodes were placed bilaterally through the small cranial burr holes over the posterior and frontal cortices and were fixed in place with cyanoacrylate glue and dental cement (Lang Dental Manufacturing Co., Inc., Wheeling, IL). Similarly, one reference electrode was placed above the cerebellum. A ground electrode was inserted subcutaneously over the back. EMG electrodes were placed in back muscles. Only 2 electrodes were implanted in the young <italic>Nestin-cre;E545K</italic> mutant and control mice. Mice were allowed to recover from surgery for 2-3 days. Simultaneous video-EEG-EMG recordings were collected from conscious mice on a PowerLab 8/35 data acquisition unit using LabChart 7.3.3 software (AD Instruments, Colorado Spring, Co). All bioelectrical signals were acquired at 1KHz sampling rate. The EEG signals were processed off-line with a 1-70 Hz bandpass filter and the ECG signals with a 3-Hz highpass filter. Interictal spikes were identified as transient, clearly distinguished from background activity, with pointed peak and short duration. Myoclonic seizures were identified as shock-like jerks of the muscles on video associated with a spike or polyspike-wave complex on EEG.</p></sec><sec id="s4-8"><title>Reverse phase protein array (RPPA) analysis</title><p>Cortex and hippocampus were dissected out of P35 control and <italic>E545K</italic> mutant mice, following different treatments (vehicle only (-), +BKM120, +PTZ, BKM120+PTZ), and flash-frozen in liquid nitrogen then sent to the RPPA Core Facility at MD Anderson Cancer Center, University of Texas. Three independent biological replicates per sample were analyzed. Analysis was performed as previously described (<xref ref-type="bibr" rid="bib67">Tibes et al., 2006</xref>). The mouse brain tissue samples were lysed and underwent protein extraction. Cellular protein was denatured by SDS sample buffer and serial dilution was made for each sample. Cell lysates were then probed with different validated antibodies. Signals were detected by DAB colorimetric reaction and intensity was quantified using ArrayPro software. Protein concentration was determined by super curve fitting. All the data points were normalized for protein loading and transformed to linear value. These linear values were used to make bar graphs for comparative analysis. See <italic><ext-link ext-link-type="uri" xlink:href="http://www.mdanderson.org/education-and-research/resources-for-professionals/scientific-resources/core-facilities-and-services/functional-proteomics-rppa-core/index.html">http://www.mdanderson.org/education-and-research/resources-for-professionals/scientific-resources/core-facilities-and-services/functional-proteomics-rppa-core/index.html</ext-link></italic>) for a detailed antibody list and protocols.</p></sec><sec id="s4-9"><title>Quantitative analysis</title><p>For quantitative analysis of embryos, data was collected from comparable sections of a minimum of 3 embryos of each genotype (from 2 or more independent litters) at each developmental stage. Cortical length was measured in the lateral ventricular lining from the tip of the fimbria/cortical hem to the pallial-subpallial boundary. Cortical length and thickness were measured using ImageJ software (NIH, Bethesda, Maryland, USA); the data was normalized to the control value. Cell counts from E14.5 and E16.5 brains were obtained from 25% of the neocortex. Area of interest was derived by dividing the whole length of neocortex into quarters and then taking images of the total area, from pia to ventricle, in the third quartile from dorsal midline. Confocal stacks of immunostained sections of each developmental stage were generated by scanning at intervals of 0.99 μm using ﬁlters of appropriate wavelengths at 20X and 40X magnifications. Confocal images of DAPI-stained brain sections and NeuN/pS6-immunostained sections were used to measure nuclear and cell size respectively. Measurements for labeling index, quit fraction, birthdating studies, cell density and size were calculated using ImageJ. For zonal quantification of cells, the cortical column was divided into 5 different parts – the ventricular-subventricular zone (vz/svz), white matter, and 3 equally divided zones of the neocortical plate (lower, mid, upper).</p><p>Statistical significance was assessed using 2-tailed unpaired t-tests (for cortical length and thickness, cell density, nuclear size, TUNEL assay, labeling index, quit fraction, total cell counts and seizure data) and ANOVA followed by Bonferroni (for cell size, BKM treatment data, birthdating experiments) and Tukey (for RPPA graphs) post-tests. These analyses were performed in GraphPad Prism v5.01 (GraphPad Software Inc., San Diego, USA) or in Igor Pro v6.3.6.4, Igor Pro Software, Lake Oswego, USA. Differences were considered significant at P&lt; 0.05.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Leon Murphy (Novartis) for BKM120, Taylor Faubion for technical support, Joseph Gleeson for sharing unpublished data and Ghayda Mirzaa and Laura Jansen for discussions.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>AR, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>JS, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>FK, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con4"><p>JN, Conception and design, Acquisition of data, Analysis and interpretation of data, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con5"><p>SR, Conception and design, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con6"><p>YL, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con7"><p>WBD, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con8"><p>GBM, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con9"><p>JJZ, Conception and design, Analysis and interpretation of data, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con10"><p>SJB, Conception and design, Analysis and interpretation of data, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con11"><p>KJM, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experimentation done in this study was done in accordance with the guidelines laid down by the Institutional Animal Care and Use Committees (IACUC) of Seattle Children's Research Institute, Seattle, WA (protocols 14208 and 14395), St. Jude Children's Research Hospital, Memphis, TN (protocol 278), and Dana Farber Cancer Institute, Boston, MA (protocol 06-034).</p></fn> </fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.12703.024</object-id><label>Supplementary file 1.</label><caption><title>Parameters for motor rotation in LabChart 8 Software</title><p>Table shows the list of parameters customized in the stimulator panel dialog box of LabChart 8 Software, in order to randomize the speed and direction of rotation of the motor used for the sleep deprivation study. The stimulation program cycle, comprising segments 1–12, was repeated through the entire duration of the sleep deprivation experiment (i.e. for 5 hr).</p> <p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12703.024">http://dx.doi.org/10.7554/eLife.12703.024</ext-link></p></caption><media mime-subtype="msword" mimetype="application" xlink:href="elife-12703-supp1-v2.doc"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamsbaum</surname><given-names>C</given-names></name><name><surname>Robain</surname><given-names>O</given-names></name><name><surname>Cohen</surname><given-names>PA</given-names></name><name><surname>Delalande</surname><given-names>O</given-names></name><name><surname>Fohlen</surname><given-names>M</given-names></name><name><surname>Kalifa</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Focal cortical dysplasia and hemimegalencephaly: histological and neuroimaging correlations</article-title><source>Pediatric Radiology</source><volume>28</volume><fpage>583</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1007/s002470050421</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>A</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Hanai</surname><given-names>S</given-names></name><name><surname>Sukigara</surname><given-names>S</given-names></name><name><surname>Nabatame</surname><given-names>S</given-names></name><name><surname>Otsuki</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>E</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Kaneko</surname><given-names>Y</given-names></name><name><surname>Kaido</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Sugai</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>Y</given-names></name><name><surname>Itoh</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Abnormal maturation and differentiation of neocortical neurons in epileptogenic cortical malformation: unique distribution of layer-specific marker cells of focal cortical dysplasia and hemimegalencephaly</article-title><source>Brain Research</source><volume>1470</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2012.06.009</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backman</surname><given-names>SA</given-names></name><name><surname>Stambolic</surname><given-names>V</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><name><surname>Haight</surname><given-names>J</given-names></name><name><surname>Elia</surname><given-names>A</given-names></name><name><surname>Pretorius</surname><given-names>J</given-names></name><name><surname>Tsao</surname><given-names>MS</given-names></name><name><surname>Shannon</surname><given-names>P</given-names></name><name><surname>Bolon</surname><given-names>B</given-names></name><name><surname>Ivy</surname><given-names>GO</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Deletion of pten in mouse brain causes seizures, ataxia and defects in soma size resembling lhermitte-duclos disease</article-title><source>Nature Genetics</source><volume>29</volume><fpage>396</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1038/ng782</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>ST</given-names></name><name><surname>Copeland</surname><given-names>B</given-names></name><name><surname>Yun</surname><given-names>EJ</given-names></name><name><surname>Kwon</surname><given-names>SK</given-names></name><name><surname>Guemez-Gamboa</surname><given-names>A</given-names></name><name><surname>Schaffer</surname><given-names>AE</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>HC</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Mathern</surname><given-names>GW</given-names></name><name><surname>Gleeson</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>An AKT3-FOXG1-reelin network underlies defective migration in human focal malformations of cortical development</article-title><source>Nature Medicine</source><volume>21</volume><fpage>1445</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1038/nm.3982</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bast</surname><given-names>T</given-names></name><name><surname>Ramantani</surname><given-names>G</given-names></name><name><surname>Seitz</surname><given-names>A</given-names></name><name><surname>Rating</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Focal cortical dysplasia: prevalence, clinical presentation and epilepsy in children and adults</article-title><source>Acta Neurologica Scandinavica</source><volume>113</volume><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0404.2005.00555.x</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batista-Brito</surname><given-names>R</given-names></name><name><surname>Fishell</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The developmental integration of cortical interneurons into a functional network</article-title><source>Current Topics in Developmental Biology</source><volume>87</volume><fpage>81</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/S0070-2153(09)01203-4</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendell</surname><given-names>JC</given-names></name><name><surname>Rodon</surname><given-names>J</given-names></name><name><surname>Burris</surname><given-names>HA</given-names></name><name><surname>de Jonge</surname><given-names>M</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Birle</surname><given-names>D</given-names></name><name><surname>Demanse</surname><given-names>D</given-names></name><name><surname>De Buck</surname><given-names>SS</given-names></name><name><surname>Ru</surname><given-names>QC</given-names></name><name><surname>Peters</surname><given-names>M</given-names></name><name><surname>Goldbrunner</surname><given-names>M</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Phase i, dose-escalation study of BKM120, an oral pan-class i PI3K inhibitor, in patients with advanced solid tumors</article-title><source>Journal of Clinical Oncology</source><volume>30</volume><fpage>282</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.36.1360</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernasconi</surname><given-names>A</given-names></name><name><surname>Bernasconi</surname><given-names>N</given-names></name><name><surname>Bernhardt</surname><given-names>BC</given-names></name><name><surname>Schrader</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Advances in MRI for 'cryptogenic' epilepsies</article-title><source>Nature Reviews. Neurology</source><volume>7</volume><fpage>99</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2010.199</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binnie</surname><given-names>CD</given-names></name><name><surname>Prior</surname><given-names>PF</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Electroencephalography</article-title><source>Journal of Neurology, Neurosurgery &amp; Psychiatry</source><volume>57</volume><fpage>1308</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1136/jnnp.57.11.1308</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blümcke</surname><given-names>I</given-names></name><name><surname>Thom</surname><given-names>M</given-names></name><name><surname>Aronica</surname><given-names>E</given-names></name><name><surname>Armstrong</surname><given-names>DD</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Palmini</surname><given-names>A</given-names></name><name><surname>Jacques</surname><given-names>TS</given-names></name><name><surname>Avanzini</surname><given-names>G</given-names></name><name><surname>Barkovich</surname><given-names>AJ</given-names></name><name><surname>Battaglia</surname><given-names>G</given-names></name><name><surname>Becker</surname><given-names>A</given-names></name><name><surname>Cepeda</surname><given-names>C</given-names></name><name><surname>Cendes</surname><given-names>F</given-names></name><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>Crino</surname><given-names>P</given-names></name><name><surname>Cross</surname><given-names>JH</given-names></name><name><surname>Delalande</surname><given-names>O</given-names></name><name><surname>Dubeau</surname><given-names>F</given-names></name><name><surname>Duncan</surname><given-names>J</given-names></name><name><surname>Guerrini</surname><given-names>R</given-names></name><name><surname>Kahane</surname><given-names>P</given-names></name><name><surname>Mathern</surname><given-names>G</given-names></name><name><surname>Najm</surname><given-names>I</given-names></name><name><surname>Ozkara</surname><given-names>C</given-names></name><name><surname>Raybaud</surname><given-names>C</given-names></name><name><surname>Represa</surname><given-names>A</given-names></name><name><surname>Roper</surname><given-names>SN</given-names></name><name><surname>Salamon</surname><given-names>N</given-names></name><name><surname>Schulze-Bonhage</surname><given-names>A</given-names></name><name><surname>Tassi</surname><given-names>L</given-names></name><name><surname>Vezzani</surname><given-names>A</given-names></name><name><surname>Spreafico</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc task force of the ILAE diagnostic methods commission</article-title><source>Epilepsia</source><volume>52</volume><fpage>158</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02777.x</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brachmann</surname><given-names>SM</given-names></name><name><surname>Kleylein-Sohn</surname><given-names>J</given-names></name><name><surname>Gaulis</surname><given-names>S</given-names></name><name><surname>Kauffmann</surname><given-names>A</given-names></name><name><surname>Blommers</surname><given-names>MJ</given-names></name><name><surname>Kazic-Legueux</surname><given-names>M</given-names></name><name><surname>Laborde</surname><given-names>L</given-names></name><name><surname>Hattenberger</surname><given-names>M</given-names></name><name><surname>Stauffer</surname><given-names>F</given-names></name><name><surname>Vaxelaire</surname><given-names>J</given-names></name><name><surname>Romanet</surname><given-names>V</given-names></name><name><surname>Henry</surname><given-names>C</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Guthy</surname><given-names>DA</given-names></name><name><surname>Sterker</surname><given-names>D</given-names></name><name><surname>Bergling</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Brümmendorf</surname><given-names>T</given-names></name><name><surname>Fritsch</surname><given-names>C</given-names></name><name><surname>Garcia-Echeverria</surname><given-names>C</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Hofmann</surname><given-names>F</given-names></name><name><surname>Maira</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Characterization of the mechanism of action of the pan class i PI3K inhibitor NVP-BKM120 across a broad range of concentrations</article-title><source>Molecular Cancer Therapeutics</source><volume>11</volume><fpage>1747</fpage><lpage>1757</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-1021</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>M</given-names></name><name><surname>R. Testa</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Diverse mechanisms of AKT pathway activation in human malignancy</article-title><source>Curr Cancer Drug Targets</source><volume>13</volume><fpage>234</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.2174/1568009611313030002</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chizhikov</surname><given-names>VV</given-names></name><name><surname>Lindgren</surname><given-names>AG</given-names></name><name><surname>Currle</surname><given-names>DS</given-names></name><name><surname>Rose</surname><given-names>MF</given-names></name><name><surname>Monuki</surname><given-names>ES</given-names></name><name><surname>Millen</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The roof plate regulates cerebellar cell-type specification and proliferation</article-title><source>Development</source><volume>133</volume><fpage>2793</fpage><lpage>2804</lpage><pub-id pub-id-type="doi">10.1242/dev.02441</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>AS</given-names></name><name><surname>Townsend</surname><given-names>KN</given-names></name><name><surname>Xiang</surname><given-names>QS</given-names></name><name><surname>Attariwala</surname><given-names>R</given-names></name><name><surname>Borchers</surname><given-names>C</given-names></name><name><surname>Senger</surname><given-names>C</given-names></name><name><surname>Picker</surname><given-names>W</given-names></name><name><surname>Levi</surname><given-names>J</given-names></name><name><surname>Yewchuk</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Eydoux</surname><given-names>P</given-names></name><name><surname>Lum</surname><given-names>A</given-names></name><name><surname>Yong</surname><given-names>SL</given-names></name><name><surname>McKinnon</surname><given-names>ML</given-names></name><name><surname>Lear</surname><given-names>SA</given-names></name><name><surname>Everett</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>SJ</given-names></name><name><surname>Yip</surname><given-names>S</given-names></name><name><surname>Gibson</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Somatic mosaicism for the p.His1047Arg mutation in PIK3CA in a girl with mesenteric lipomatosis</article-title><source>American Journal of Medical Genetics. Part A</source><volume>164A</volume><fpage>2360</fpage><lpage>2364</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.36622</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname><given-names>RL</given-names></name><name><surname>Pressman</surname><given-names>BD</given-names></name><name><surname>Dobyns</surname><given-names>WB</given-names></name><name><surname>Danielpour</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Sanchez-Lara</surname><given-names>PA</given-names></name><name><surname>Butler</surname><given-names>MG</given-names></name><name><surname>Zackai</surname><given-names>E</given-names></name><name><surname>Campbell</surname><given-names>L</given-names></name><name><surname>Saitta</surname><given-names>SC</given-names></name><name><surname>Clericuzio</surname><given-names>CL</given-names></name><name><surname>Milunsky</surname><given-names>JM</given-names></name><name><surname>Hoyme</surname><given-names>HE</given-names></name><name><surname>Shieh</surname><given-names>J</given-names></name><name><surname>Moeschler</surname><given-names>JB</given-names></name><name><surname>Crandall</surname><given-names>B</given-names></name><name><surname>Lauzon</surname><given-names>JL</given-names></name><name><surname>Viskochil</surname><given-names>DH</given-names></name><name><surname>Harding</surname><given-names>B</given-names></name><name><surname>Graham</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Neuroimaging findings in macrocephaly-capillary malformation: a longitudinal study of 17 patients</article-title><source>American Journal of Medical Genetics. Part A</source><volume>143A</volume><fpage>2981</fpage><lpage>3008</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.32040</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curatolo</surname><given-names>P</given-names></name><name><surname>Moavero</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>MTOR inhibitors as a new therapeutic option for epilepsy</article-title><source>Expert Review of Neurotherapeutics</source><volume>13</volume><fpage>627</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1586/ern.13.49</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Gama</surname><given-names>AM</given-names></name><name><surname>Geng</surname><given-names>Y</given-names></name><name><surname>Couto</surname><given-names>JA</given-names></name><name><surname>Martin</surname><given-names>B</given-names></name><name><surname>Boyle</surname><given-names>EA</given-names></name><name><surname>LaCoursiere</surname><given-names>CM</given-names></name><name><surname>Hossain</surname><given-names>A</given-names></name><name><surname>Hatem</surname><given-names>NE</given-names></name><name><surname>Barry</surname><given-names>BJ</given-names></name><name><surname>Kwiatkowski</surname><given-names>DJ</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Barkovich</surname><given-names>AJ</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Mathern</surname><given-names>GW</given-names></name><name><surname>Walsh</surname><given-names>CA</given-names></name><name><surname>Poduri</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia</article-title><source>Annals of Neurology</source><volume>77</volume><fpage>720</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1002/ana.24357</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rosa</surname><given-names>MJ</given-names></name><name><surname>Secor</surname><given-names>DL</given-names></name><name><surname>Barsom</surname><given-names>M</given-names></name><name><surname>Fisher</surname><given-names>RS</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Neuropathologic findings in surgically treated hemimegalencephaly: immunohistochemical, morphometric, and ultrastructural study</article-title><source>Acta Neuropathologica</source><volume>84</volume><fpage>250</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1007/BF00227817</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devlin</surname><given-names>AM</given-names></name><name><surname>Cross</surname><given-names>JH</given-names></name><name><surname>Harkness</surname><given-names>W</given-names></name><name><surname>Chong</surname><given-names>WK</given-names></name><name><surname>Harding</surname><given-names>B</given-names></name><name><surname>Vargha-Khadem</surname><given-names>F</given-names></name><name><surname>Neville</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Clinical outcomes of hemispherectomy for epilepsy in childhood and adolescence</article-title><source>Brain</source><volume>126</volume><fpage>556</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1093/brain/awg052</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelman</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Targeting PI3K signalling in cancer: opportunities, challenges and limitations</article-title><source>Nature Reviews. Cancer</source><volume>9</volume><fpage>550</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1038/nrc2664</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauser</surname><given-names>S</given-names></name><name><surname>Essang</surname><given-names>C</given-names></name><name><surname>Altenmüller</surname><given-names>DM</given-names></name><name><surname>Staack</surname><given-names>AM</given-names></name><name><surname>Steinhoff</surname><given-names>BJ</given-names></name><name><surname>Strobl</surname><given-names>K</given-names></name><name><surname>Bast</surname><given-names>T</given-names></name><name><surname>Schubert-Bast</surname><given-names>S</given-names></name><name><surname>Stephani</surname><given-names>U</given-names></name><name><surname>Wiegand</surname><given-names>G</given-names></name><name><surname>Prinz</surname><given-names>M</given-names></name><name><surname>Brandt</surname><given-names>A</given-names></name><name><surname>Zentner</surname><given-names>J</given-names></name><name><surname>Schulze-Bonhage</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Long-term seizure outcome in 211 patients with focal cortical dysplasia</article-title><source>Epilepsia</source><volume>56</volume><fpage>66</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1111/epi.12876</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauser</surname><given-names>S</given-names></name><name><surname>Huppertz</surname><given-names>HJ</given-names></name><name><surname>Bast</surname><given-names>T</given-names></name><name><surname>Strobl</surname><given-names>K</given-names></name><name><surname>Pantazis</surname><given-names>G</given-names></name><name><surname>Altenmueller</surname><given-names>DM</given-names></name><name><surname>Feil</surname><given-names>B</given-names></name><name><surname>Rona</surname><given-names>S</given-names></name><name><surname>Kurth</surname><given-names>C</given-names></name><name><surname>Rating</surname><given-names>D</given-names></name><name><surname>Korinthenberg</surname><given-names>R</given-names></name><name><surname>Steinhoff</surname><given-names>BJ</given-names></name><name><surname>Volk</surname><given-names>B</given-names></name><name><surname>Schulze-Bonhage</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Clinical characteristics in focal cortical dysplasia: a retrospective evaluation in a series of 120 patients</article-title><source>Brain</source><volume>129</volume><fpage>1907</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1093/brain/awl133</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>MM</given-names></name><name><surname>Bayazitov</surname><given-names>IT</given-names></name><name><surname>Zakharenko</surname><given-names>SS</given-names></name><name><surname>Baker</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities</article-title><source>Neuroscience</source><volume>151</volume><fpage>476</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.10.048</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>MM</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Kwon</surname><given-names>CH</given-names></name><name><surname>Uhlmann</surname><given-names>EJ</given-names></name><name><surname>Gutmann</surname><given-names>DH</given-names></name><name><surname>Baker</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo</article-title><source>Cancer Research</source><volume>64</volume><fpage>7773</fpage><lpage>7779</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2487</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fruman</surname><given-names>DA</given-names></name><name><surname>Mauvais-Jarvis</surname><given-names>F</given-names></name><name><surname>Pollard</surname><given-names>DA</given-names></name><name><surname>Yballe</surname><given-names>CM</given-names></name><name><surname>Brazil</surname><given-names>D</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Kahn</surname><given-names>CR</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha</article-title><source>Nature Genetics</source><volume>26</volume><fpage>379</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1038/81715</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geering</surname><given-names>B</given-names></name><name><surname>Cutillas</surname><given-names>PR</given-names></name><name><surname>Nock</surname><given-names>G</given-names></name><name><surname>Gharbi</surname><given-names>SI</given-names></name><name><surname>Vanhaesebroeck</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>104</volume><fpage>7809</fpage><lpage>7814</lpage><pub-id pub-id-type="doi">10.1073/pnas.0700373104</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giorgi</surname><given-names>FS</given-names></name><name><surname>Maestri</surname><given-names>M</given-names></name><name><surname>Guida</surname><given-names>M</given-names></name><name><surname>Di Coscio</surname><given-names>E</given-names></name><name><surname>Carnicelli</surname><given-names>L</given-names></name><name><surname>Perini</surname><given-names>D</given-names></name><name><surname>Pizzanelli</surname><given-names>C</given-names></name><name><surname>Iudice</surname><given-names>A</given-names></name><name><surname>Bonanni</surname><given-names>E</given-names></name></person-group><year iso-8601-date="20132013">20132013</year><article-title>Controversial issues on EEG after sleep deprivation for the diagnosis of epilepsy</article-title><source>Epilepsy Research and Treatment</source><volume>2013</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1155/2013/614685</pub-id><pub-id pub-id-type="doi">10.1155/2013/614685</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groesser</surname><given-names>L</given-names></name><name><surname>Herschberger</surname><given-names>E</given-names></name><name><surname>Landthaler</surname><given-names>M</given-names></name><name><surname>Hafner</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis</article-title><source>The British Journal of Dermatology</source><volume>166</volume><fpage>784</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2011.10788.x</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gymnopoulos</surname><given-names>M</given-names></name><name><surname>Elsliger</surname><given-names>M-A</given-names></name><name><surname>Vogt</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Rare cancer-specific mutations in PIK3CA show gain of function</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>104</volume><fpage>5569</fpage><lpage>5574</lpage><pub-id pub-id-type="doi">10.1073/pnas.0701005104</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hafner</surname><given-names>C</given-names></name><name><surname>Lopez-Knowles</surname><given-names>E</given-names></name><name><surname>Luis</surname><given-names>NM</given-names></name><name><surname>Toll</surname><given-names>A</given-names></name><name><surname>Baselga</surname><given-names>E</given-names></name><name><surname>Fernandez-Casado</surname><given-names>A</given-names></name><name><surname>Hernandez</surname><given-names>S</given-names></name><name><surname>Ribe</surname><given-names>A</given-names></name><name><surname>Mentzel</surname><given-names>T</given-names></name><name><surname>Stoehr</surname><given-names>R</given-names></name><name><surname>Hofstaedter</surname><given-names>F</given-names></name><name><surname>Landthaler</surname><given-names>M</given-names></name><name><surname>Vogt</surname><given-names>T</given-names></name><name><surname>Pujol</surname><given-names>RM</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Real</surname><given-names>FX</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>104</volume><fpage>13450</fpage><lpage>13454</lpage><pub-id pub-id-type="doi">10.1073/pnas.0705218104</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennessy</surname><given-names>BT</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Ram</surname><given-names>PT</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Exploiting the PI3K/AKT pathway for cancer drug discovery</article-title><source>Nature Reviews. Drug Discovery</source><volume>4</volume><fpage>988</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1038/nrd1902</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwabuchi</surname><given-names>H</given-names></name><name><surname>Sakamoto</surname><given-names>M</given-names></name><name><surname>Sakunaga</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>YY</given-names></name><name><surname>Carcangiu</surname><given-names>ML</given-names></name><name><surname>Pinkel</surname><given-names>D</given-names></name><name><surname>Yang-Feng</surname><given-names>TL</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Genetic analysis of benign, low-grade, and high-grade ovarian tumors</article-title><source>Cancer Research</source><volume>55</volume><fpage>6172</fpage><lpage>6180</lpage></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>LA</given-names></name><name><surname>Mirzaa</surname><given-names>GM</given-names></name><name><surname>Ishak</surname><given-names>GE</given-names></name><name><surname>O'Roak</surname><given-names>BJ</given-names></name><name><surname>Hiatt</surname><given-names>JB</given-names></name><name><surname>Roden</surname><given-names>WH</given-names></name><name><surname>Gunter</surname><given-names>SA</given-names></name><name><surname>Christian</surname><given-names>SL</given-names></name><name><surname>Collins</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>C</given-names></name><name><surname>Rivière</surname><given-names>J-B</given-names></name><name><surname>St-Onge</surname><given-names>J</given-names></name><name><surname>Ojemann</surname><given-names>JG</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Hevner</surname><given-names>RF</given-names></name><name><surname>Dobyns</surname><given-names>WB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia</article-title><source>Brain</source><volume>138</volume><fpage>1613</fpage><lpage>1628</lpage><pub-id pub-id-type="doi">10.1093/brain/awv045</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>LA</given-names></name><name><surname>Mirzaa</surname><given-names>GM</given-names></name><name><surname>Ishak</surname><given-names>GE</given-names></name><name><surname>O'Roak</surname><given-names>BJ</given-names></name><name><surname>Hiatt</surname><given-names>JB</given-names></name><name><surname>Roden</surname><given-names>WH</given-names></name><name><surname>Gunter</surname><given-names>SA</given-names></name><name><surname>Christian</surname><given-names>SL</given-names></name><name><surname>Collins</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>C</given-names></name><name><surname>Rivière</surname><given-names>JB</given-names></name><name><surname>St-Onge</surname><given-names>J</given-names></name><name><surname>Ojemann</surname><given-names>JG</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Hevner</surname><given-names>RF</given-names></name><name><surname>Dobyns</surname><given-names>WB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia</article-title><source>Brain : A Journal of Neurology</source><volume>138</volume><fpage>1613</fpage><lpage>1628</lpage><pub-id pub-id-type="doi">10.1093/brain/awv045</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalume</surname><given-names>F</given-names></name><name><surname>Oakley</surname><given-names>JC</given-names></name><name><surname>Westenbroek</surname><given-names>RE</given-names></name><name><surname>Gile</surname><given-names>J</given-names></name><name><surname>de la Iglesia</surname><given-names>HO</given-names></name><name><surname>Scheuer</surname><given-names>T</given-names></name><name><surname>Catterall</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sleep impairment and reduced interneuron excitability in a mouse model of dravet syndrome</article-title><source>Neurobiology of Disease</source><volume>77</volume><fpage>141</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2015.02.016</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalume</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Sudden unexpected death in dravet syndrome: respiratory and other physiological dysfunctions</article-title><source>Respiratory Physiology &amp; Neurobiology</source><volume>189</volume><fpage>324</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.resp.2013.06.026</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keppler-Noreuil</surname><given-names>KM</given-names></name><name><surname>Sapp</surname><given-names>JC</given-names></name><name><surname>Lindhurst</surname><given-names>MJ</given-names></name><name><surname>Parker</surname><given-names>VE</given-names></name><name><surname>Blumhorst</surname><given-names>C</given-names></name><name><surname>Darling</surname><given-names>T</given-names></name><name><surname>Tosi</surname><given-names>LL</given-names></name><name><surname>Huson</surname><given-names>SM</given-names></name><name><surname>Whitehouse</surname><given-names>RW</given-names></name><name><surname>Jakkula</surname><given-names>E</given-names></name><name><surname>Grant</surname><given-names>I</given-names></name><name><surname>Balasubramanian</surname><given-names>M</given-names></name><name><surname>Chandler</surname><given-names>KE</given-names></name><name><surname>Fraser</surname><given-names>JL</given-names></name><name><surname>Gucev</surname><given-names>Z</given-names></name><name><surname>Crow</surname><given-names>YJ</given-names></name><name><surname>Brennan</surname><given-names>LM</given-names></name><name><surname>Clark</surname><given-names>R</given-names></name><name><surname>Sellars</surname><given-names>EA</given-names></name><name><surname>Pena</surname><given-names>LD</given-names></name><name><surname>Krishnamurty</surname><given-names>V</given-names></name><name><surname>Shuen</surname><given-names>A</given-names></name><name><surname>Braverman</surname><given-names>N</given-names></name><name><surname>Cunningham</surname><given-names>ML</given-names></name><name><surname>Sutton</surname><given-names>VR</given-names></name><name><surname>Tasic</surname><given-names>V</given-names></name><name><surname>Graham</surname><given-names>JM</given-names></name><name><surname>Geer</surname><given-names>J</given-names></name><name><surname>Henderson</surname><given-names>A</given-names></name><name><surname>Semple</surname><given-names>RK</given-names></name><name><surname>Biesecker</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum</article-title><source>American Journal of Medical Genetics</source><volume>164A</volume><fpage>1713</fpage><lpage>1733</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.36552</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinross</surname><given-names>KM</given-names></name><name><surname>Montgomery</surname><given-names>KG</given-names></name><name><surname>Kleinschmidt</surname><given-names>M</given-names></name><name><surname>Waring</surname><given-names>P</given-names></name><name><surname>Ivetac</surname><given-names>I</given-names></name><name><surname>Tikoo</surname><given-names>A</given-names></name><name><surname>Saad</surname><given-names>M</given-names></name><name><surname>Hare</surname><given-names>L</given-names></name><name><surname>Roh</surname><given-names>V</given-names></name><name><surname>Mantamadiotis</surname><given-names>T</given-names></name><name><surname>Sheppard</surname><given-names>KE</given-names></name><name><surname>Ryland</surname><given-names>GL</given-names></name><name><surname>Campbell</surname><given-names>IG</given-names></name><name><surname>Gorringe</surname><given-names>KL</given-names></name><name><surname>Christensen</surname><given-names>JG</given-names></name><name><surname>Cullinane</surname><given-names>C</given-names></name><name><surname>Hicks</surname><given-names>RJ</given-names></name><name><surname>Pearson</surname><given-names>RB</given-names></name><name><surname>Johnstone</surname><given-names>RW</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Phillips</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>An activating Pik3ca mutation coupled with pten loss is sufficient to initiate ovarian tumorigenesis in mice</article-title><source>The Journal of Clinical Investigation</source><volume>122</volume><fpage>553</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1172/JCI59309</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Zhang</surname><given-names>MX</given-names></name><name><surname>Swank</surname><given-names>MW</given-names></name><name><surname>Kunz</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>GY</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Regulation of dendritic morphogenesis by ras-PI3K-akt-mTOR and ras-MAPK signaling pathways</article-title><source>The Journal of Neuroscience</source><volume>25</volume><fpage>11288</fpage><lpage>11299</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2284-05.2005</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurek</surname><given-names>KC</given-names></name><name><surname>Luks</surname><given-names>VL</given-names></name><name><surname>Ayturk</surname><given-names>UM</given-names></name><name><surname>Alomari</surname><given-names>AI</given-names></name><name><surname>Fishman</surname><given-names>SJ</given-names></name><name><surname>Spencer</surname><given-names>SA</given-names></name><name><surname>Mulliken</surname><given-names>JB</given-names></name><name><surname>Bowen</surname><given-names>ME</given-names></name><name><surname>Yamamoto</surname><given-names>GL</given-names></name><name><surname>Kozakewich</surname><given-names>HP</given-names></name><name><surname>Warman</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome</article-title><source>American Journal of Human Genetics</source><volume>90</volume><fpage>1108</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2012.05.006</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>CH</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Knoop</surname><given-names>LL</given-names></name><name><surname>Tharp</surname><given-names>R</given-names></name><name><surname>Smeyne</surname><given-names>RJ</given-names></name><name><surname>Eberhart</surname><given-names>CG</given-names></name><name><surname>Burger</surname><given-names>PC</given-names></name><name><surname>Baker</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Pten regulates neuronal soma size: a mouse model of lhermitte-duclos disease</article-title><source>Nature Genetics</source><volume>29</volume><fpage>404</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1038/ng781</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Huynh</surname><given-names>M</given-names></name><name><surname>Silhavy</surname><given-names>JL</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Dixon-Salazar</surname><given-names>T</given-names></name><name><surname>Heiberg</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>E</given-names></name><name><surname>Bafna</surname><given-names>V</given-names></name><name><surname>Hill</surname><given-names>KJ</given-names></name><name><surname>Collazo</surname><given-names>A</given-names></name><name><surname>Funari</surname><given-names>V</given-names></name><name><surname>Russ</surname><given-names>C</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Mathern</surname><given-names>GW</given-names></name><name><surname>Gleeson</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly</article-title><source>Nature Genetics</source><volume>44</volume><fpage>941</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1038/ng.2329</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>WI</given-names></name><name><surname>Kang</surname><given-names>HC</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>AH</given-names></name><name><surname>Park</surname><given-names>EK</given-names></name><name><surname>Cho</surname><given-names>YW</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Rhee</surname><given-names>H</given-names></name><name><surname>Kang</surname><given-names>SG</given-names></name><name><surname>Kim</surname><given-names>HD</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy</article-title><source>Nature Medicine</source><volume>21</volume><fpage>395</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1038/nm.3824</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindhurst</surname><given-names>MJ</given-names></name><name><surname>Parker</surname><given-names>VE</given-names></name><name><surname>Payne</surname><given-names>F</given-names></name><name><surname>Sapp</surname><given-names>JC</given-names></name><name><surname>Rudge</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>Witkowski</surname><given-names>AM</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Groeneveld</surname><given-names>MP</given-names></name><name><surname>Scott</surname><given-names>CE</given-names></name><name><surname>Daly</surname><given-names>A</given-names></name><name><surname>Huson</surname><given-names>SM</given-names></name><name><surname>Tosi</surname><given-names>LL</given-names></name><name><surname>Cunningham</surname><given-names>ML</given-names></name><name><surname>Darling</surname><given-names>TN</given-names></name><name><surname>Geer</surname><given-names>J</given-names></name><name><surname>Gucev</surname><given-names>Z</given-names></name><name><surname>Sutton</surname><given-names>VR</given-names></name><name><surname>Tziotzios</surname><given-names>C</given-names></name><name><surname>Dixon</surname><given-names>AK</given-names></name><name><surname>Helliwell</surname><given-names>T</given-names></name><name><surname>O'Rahilly</surname><given-names>S</given-names></name><name><surname>Savage</surname><given-names>DB</given-names></name><name><surname>Wakelam</surname><given-names>MJ</given-names></name><name><surname>Barroso</surname><given-names>I</given-names></name><name><surname>Biesecker</surname><given-names>LG</given-names></name><name><surname>Semple</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA</article-title><source>Nature Genetics</source><volume>44</volume><fpage>928</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1038/ng.2332</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Santiago</surname><given-names>S</given-names></name><name><surname>Raeder</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Isabella</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Semaan</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Fox</surname><given-names>EA</given-names></name><name><surname>Gray</surname><given-names>NS</given-names></name><name><surname>Monahan</surname><given-names>J</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms</article-title><source>Nature Medicine</source><volume>17</volume><fpage>1116</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1038/nm.2402</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luks</surname><given-names>VL</given-names></name><name><surname>Kamitaki</surname><given-names>N</given-names></name><name><surname>Vivero</surname><given-names>MP</given-names></name><name><surname>Uller</surname><given-names>W</given-names></name><name><surname>Rab</surname><given-names>R</given-names></name><name><surname>Bovée</surname><given-names>JV</given-names></name><name><surname>Rialon</surname><given-names>KL</given-names></name><name><surname>Guevara</surname><given-names>CJ</given-names></name><name><surname>Alomari</surname><given-names>AI</given-names></name><name><surname>Greene</surname><given-names>AK</given-names></name><name><surname>Fishman</surname><given-names>SJ</given-names></name><name><surname>Kozakewich</surname><given-names>HP</given-names></name><name><surname>Maclellan</surname><given-names>RA</given-names></name><name><surname>Mulliken</surname><given-names>JB</given-names></name><name><surname>Rahbar</surname><given-names>R</given-names></name><name><surname>Spencer</surname><given-names>SA</given-names></name><name><surname>Trenor</surname><given-names>CC</given-names></name><name><surname>Upton</surname><given-names>J</given-names></name><name><surname>Zurakowski</surname><given-names>D</given-names></name><name><surname>Perkins</surname><given-names>JA</given-names></name><name><surname>Kirsh</surname><given-names>A</given-names></name><name><surname>Bennett</surname><given-names>JT</given-names></name><name><surname>Dobyns</surname><given-names>WB</given-names></name><name><surname>Kurek</surname><given-names>KC</given-names></name><name><surname>Warman</surname><given-names>ML</given-names></name><name><surname>McCarroll</surname><given-names>SA</given-names></name><name><surname>Murillo</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA</article-title><source>The Journal of Pediatrics</source><volume>166</volume><fpage>1048</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2014.12.069</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>RL</given-names></name><name><surname>Barker</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Specific antagonism of GABA-mediated postsynaptic inhibition in cultured mammalian spinal cord neurons: a common mode of convulsant action</article-title><source>Neurology</source><volume>28</volume><fpage>325</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1212/WNL.28.4.325</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maira</surname><given-names>SM</given-names></name><name><surname>Pecchi</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Burger</surname><given-names>M</given-names></name><name><surname>Knapp</surname><given-names>M</given-names></name><name><surname>Sterker</surname><given-names>D</given-names></name><name><surname>Schnell</surname><given-names>C</given-names></name><name><surname>Guthy</surname><given-names>D</given-names></name><name><surname>Nagel</surname><given-names>T</given-names></name><name><surname>Wiesmann</surname><given-names>M</given-names></name><name><surname>Brachmann</surname><given-names>S</given-names></name><name><surname>Fritsch</surname><given-names>C</given-names></name><name><surname>Dorsch</surname><given-names>M</given-names></name><name><surname>Chène</surname><given-names>P</given-names></name><name><surname>Shoemaker</surname><given-names>K</given-names></name><name><surname>De Pover</surname><given-names>A</given-names></name><name><surname>Menezes</surname><given-names>D</given-names></name><name><surname>Martiny-Baron</surname><given-names>G</given-names></name><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>CJ</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Hofmann</surname><given-names>F</given-names></name><name><surname>García-Echeverría</surname><given-names>C</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Voliva</surname><given-names>CF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identification and characterization of NVP-BKM120, an orally available pan-class i PI3-kinase inhibitor</article-title><source>Molecular Cancer Therapeutics</source><volume>11</volume><fpage>317</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0474</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>DS</given-names></name><name><surname>Brinkhaus</surname><given-names>H</given-names></name><name><surname>Müller</surname><given-names>U</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Cardiff</surname><given-names>RD</given-names></name><name><surname>Bentires-Alj</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors</article-title><source>Cancer Research</source><volume>71</volume><fpage>4344</fpage><lpage>4351</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-3827</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miled</surname><given-names>N</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Hon</surname><given-names>WC</given-names></name><name><surname>Perisic</surname><given-names>O</given-names></name><name><surname>Zvelebil</surname><given-names>M</given-names></name><name><surname>Inbar</surname><given-names>Y</given-names></name><name><surname>Schneidman-Duhovny</surname><given-names>D</given-names></name><name><surname>Wolfson</surname><given-names>HJ</given-names></name><name><surname>Backer</surname><given-names>JM</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit</article-title><source>Science</source><volume>317</volume><fpage>239</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1126/science.1135394</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirzaa</surname><given-names>GM</given-names></name><name><surname>Conway</surname><given-names>RL</given-names></name><name><surname>Gripp</surname><given-names>KW</given-names></name><name><surname>Lerman-Sagie</surname><given-names>T</given-names></name><name><surname>Siegel</surname><given-names>DH</given-names></name><name><surname>deVries</surname><given-names>LS</given-names></name><name><surname>Lev</surname><given-names>D</given-names></name><name><surname>Kramer</surname><given-names>N</given-names></name><name><surname>Hopkins</surname><given-names>E</given-names></name><name><surname>Graham</surname><given-names>JM</given-names></name><name><surname>Dobyns</surname><given-names>WB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Megalencephaly-capillary malformation (mCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (mPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis</article-title><source>American Journal of Medical Genetics. Part A</source><volume>158A</volume><fpage>269</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.34402</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>UY</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>R</given-names></name><name><surname>Cho</surname><given-names>JY</given-names></name><name><surname>Hughes</surname><given-names>LJ</given-names></name><name><surname>McKenna</surname><given-names>J</given-names></name><name><surname>Goetzl</surname><given-names>L</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name><name><surname>Crino</surname><given-names>PB</given-names></name><name><surname>Gambello</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Impaired reelin-Dab1 signaling contributes to neuronal migration deficits of tuberous sclerosis complex</article-title><source>Cell Reports</source><volume>12</volume><fpage>965</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.07.013</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osborn</surname><given-names>AJ</given-names></name><name><surname>Dickie</surname><given-names>P</given-names></name><name><surname>Neilson</surname><given-names>DE</given-names></name><name><surname>Glaser</surname><given-names>K</given-names></name><name><surname>Lynch</surname><given-names>KA</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Dickie</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>926</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu505</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquier</surname><given-names>B</given-names></name><name><surname>Péoc'H</surname><given-names>M</given-names></name><name><surname>Fabre-Bocquentin</surname><given-names>B</given-names></name><name><surname>Bensaadi</surname><given-names>L</given-names></name><name><surname>Pasquier</surname><given-names>D</given-names></name><name><surname>Hoffmann</surname><given-names>D</given-names></name><name><surname>Kahane</surname><given-names>P</given-names></name><name><surname>Tassi</surname><given-names>L</given-names></name><name><surname>Le Bas</surname><given-names>JF</given-names></name><name><surname>Benabid</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Surgical pathology of drug-resistant partial epilepsy. a 10-year-experience with a series of 327 consecutive resections</article-title><source>Epileptic Disorders</source><volume>4</volume><fpage>99</fpage><lpage>119</lpage></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Racine</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="1972">1972</year><article-title>Modification of seizure activity by electrical stimulation. II. motor seizure</article-title><source>Electroencephalography and Clinical Neurophysiology</source><volume>32</volume><fpage>281</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/0013-4694(72)90177-0</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rios</surname><given-names>JJ</given-names></name><name><surname>Paria</surname><given-names>N</given-names></name><name><surname>Burns</surname><given-names>DK</given-names></name><name><surname>Israel</surname><given-names>BA</given-names></name><name><surname>Cornelia</surname><given-names>R</given-names></name><name><surname>Wise</surname><given-names>CA</given-names></name><name><surname>Ezaki</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly</article-title><source>Human Molecular Genetics</source><volume>22</volume><fpage>444</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds440</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivière</surname><given-names>JB</given-names></name><name><surname>Mirzaa</surname><given-names>GM</given-names></name><name><surname>O'Roak</surname><given-names>BJ</given-names></name><name><surname>Beddaoui</surname><given-names>M</given-names></name><name><surname>Alcantara</surname><given-names>D</given-names></name><name><surname>Conway</surname><given-names>RL</given-names></name><name><surname>St-Onge</surname><given-names>J</given-names></name><name><surname>Schwartzentruber</surname><given-names>JA</given-names></name><name><surname>Gripp</surname><given-names>KW</given-names></name><name><surname>Nikkel</surname><given-names>SM</given-names></name><name><surname>Worthylake</surname><given-names>T</given-names></name><name><surname>Sullivan</surname><given-names>CT</given-names></name><name><surname>Ward</surname><given-names>TR</given-names></name><name><surname>Butler</surname><given-names>HE</given-names></name><name><surname>Kramer</surname><given-names>NA</given-names></name><name><surname>Albrecht</surname><given-names>B</given-names></name><name><surname>Armour</surname><given-names>CM</given-names></name><name><surname>Armstrong</surname><given-names>L</given-names></name><name><surname>Caluseriu</surname><given-names>O</given-names></name><name><surname>Cytrynbaum</surname><given-names>C</given-names></name><name><surname>Drolet</surname><given-names>BA</given-names></name><name><surname>Innes</surname><given-names>AM</given-names></name><name><surname>Lauzon</surname><given-names>JL</given-names></name><name><surname>Lin</surname><given-names>AE</given-names></name><name><surname>Mancini</surname><given-names>GM</given-names></name><name><surname>Meschino</surname><given-names>WS</given-names></name><name><surname>Reggin</surname><given-names>JD</given-names></name><name><surname>Saggar</surname><given-names>AK</given-names></name><name><surname>Lerman-Sagie</surname><given-names>T</given-names></name><name><surname>Uyanik</surname><given-names>G</given-names></name><name><surname>Weksberg</surname><given-names>R</given-names></name><name><surname>Zirn</surname><given-names>B</given-names></name><name><surname>Beaulieu</surname><given-names>CL</given-names></name><name><surname>Majewski</surname><given-names>J</given-names></name><name><surname>Bulman</surname><given-names>DE</given-names></name><name><surname>O'Driscoll</surname><given-names>M</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>JM</given-names></name><name><surname>Boycott</surname><given-names>KM</given-names></name><name><surname>Dobyns</surname><given-names>WB</given-names></name><collab>Finding of Rare Disease Genes (FORGE) Canada Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes</article-title><source>Nature Genetics</source><volume>44</volume><fpage>934</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1038/ng.2331</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>G</given-names></name><name><surname>Parker</surname><given-names>M</given-names></name><name><surname>Kranenburg</surname><given-names>TA</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Phoenix</surname><given-names>TN</given-names></name><name><surname>Hedlund</surname><given-names>E</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Chalhoub</surname><given-names>N</given-names></name><name><surname>Baker</surname><given-names>SJ</given-names></name><name><surname>Huether</surname><given-names>R</given-names></name><name><surname>Kriwacki</surname><given-names>R</given-names></name><name><surname>Curley</surname><given-names>N</given-names></name><name><surname>Thiruvenkatam</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Rusch</surname><given-names>M</given-names></name><name><surname>Hong</surname><given-names>X</given-names></name><name><surname>Becksfort</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Easton</surname><given-names>J</given-names></name><name><surname>Vadodaria</surname><given-names>B</given-names></name><name><surname>Onar-Thomas</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Pounds</surname><given-names>S</given-names></name><name><surname>Paugh</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Kawauchi</surname><given-names>D</given-names></name><name><surname>Roussel</surname><given-names>MF</given-names></name><name><surname>Finkelstein</surname><given-names>D</given-names></name><name><surname>Ellison</surname><given-names>DW</given-names></name><name><surname>Lau</surname><given-names>CC</given-names></name><name><surname>Bouffet</surname><given-names>E</given-names></name><name><surname>Hassall</surname><given-names>T</given-names></name><name><surname>Gururangan</surname><given-names>S</given-names></name><name><surname>Cohn</surname><given-names>R</given-names></name><name><surname>Fulton</surname><given-names>RS</given-names></name><name><surname>Fulton</surname><given-names>LL</given-names></name><name><surname>Dooling</surname><given-names>DJ</given-names></name><name><surname>Ochoa</surname><given-names>K</given-names></name><name><surname>Gajjar</surname><given-names>A</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Gilbertson</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Novel mutations target distinct subgroups of medulloblastoma</article-title><source>Nature</source><volume>488</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/nature11213</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossini</surname><given-names>L</given-names></name><name><surname>Medici</surname><given-names>V</given-names></name><name><surname>Tassi</surname><given-names>L</given-names></name><name><surname>Cardinale</surname><given-names>F</given-names></name><name><surname>Tringali</surname><given-names>G</given-names></name><name><surname>Bramerio</surname><given-names>M</given-names></name><name><surname>Villani</surname><given-names>F</given-names></name><name><surname>Spreafico</surname><given-names>R</given-names></name><name><surname>Garbelli</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Layer-specific gene expression in epileptogenic type II focal cortical dysplasia: normal-looking neurons reveal the presence of a hidden laminar organization</article-title><source>Acta Neuropathologica Communications</source><volume>2</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/2051-5960-2-45</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>GL</given-names></name><name><surname>Tassi</surname><given-names>L</given-names></name><name><surname>Cossu</surname><given-names>M</given-names></name><name><surname>Cardinale</surname><given-names>F</given-names></name><name><surname>Mai</surname><given-names>R</given-names></name><name><surname>Castana</surname><given-names>L</given-names></name><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>Bramerio</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Focal cortical resection in malformations of cortical development</article-title><source>Epileptic Disorders</source><volume>5 Suppl 2</volume><fpage>S115</fpage><lpage>S123</lpage></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salamon</surname><given-names>N</given-names></name><name><surname>Andres</surname><given-names>M</given-names></name><name><surname>Chute</surname><given-names>DJ</given-names></name><name><surname>Nguyen</surname><given-names>ST</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name><name><surname>Huynh</surname><given-names>MN</given-names></name><name><surname>Chandra</surname><given-names>PS</given-names></name><name><surname>Andre</surname><given-names>VM</given-names></name><name><surname>Cepeda</surname><given-names>C</given-names></name><name><surname>Levine</surname><given-names>MS</given-names></name><name><surname>Leite</surname><given-names>JP</given-names></name><name><surname>Neder</surname><given-names>L</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Mathern</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Contralateral hemimicrencephaly and clinical-pathological correlations in children with hemimegalencephaly</article-title><source>Brain</source><volume>129</volume><fpage>352</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1093/brain/awh681</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuels</surname><given-names>Y</given-names></name><name><surname>Waldman</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Oncogenic mutations of PIK3CA in human cancers</article-title><source>Curr Top Microbiol Immunol</source><volume>347</volume><fpage>21</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/82_2010_68</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sosunov</surname><given-names>AA</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Weiner</surname><given-names>HL</given-names></name><name><surname>Mikell</surname><given-names>CB</given-names></name><name><surname>Goodman</surname><given-names>RR</given-names></name><name><surname>Crino</surname><given-names>PD</given-names></name><name><surname>McKhann</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tuberous sclerosis: a primary pathology of astrocytes?</article-title><source>Epilepsia</source><volume>49 Suppl 2</volume><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1167.2008.01493.x</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stemke-Hale</surname><given-names>K</given-names></name><name><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></name><name><surname>Lluch</surname><given-names>A</given-names></name><name><surname>Neve</surname><given-names>RM</given-names></name><name><surname>Kuo</surname><given-names>WL</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Carey</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Sahin</surname><given-names>A</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name><name><surname>Pusztai</surname><given-names>L</given-names></name><name><surname>Nolden</surname><given-names>LK</given-names></name><name><surname>Horlings</surname><given-names>H</given-names></name><name><surname>Berns</surname><given-names>K</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>Valero</surname><given-names>V</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Hennessy</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer</article-title><source>Cancer Research</source><volume>68</volume><fpage>6084</fpage><lpage>6091</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6854</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tassi</surname><given-names>L</given-names></name><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>Garbelli</surname><given-names>R</given-names></name><name><surname>Francione</surname><given-names>S</given-names></name><name><surname>Lo Russo</surname><given-names>G</given-names></name><name><surname>Mai</surname><given-names>R</given-names></name><name><surname>Cardinale</surname><given-names>F</given-names></name><name><surname>Cossu</surname><given-names>M</given-names></name><name><surname>Ferrario</surname><given-names>A</given-names></name><name><surname>Galli</surname><given-names>C</given-names></name><name><surname>Bramerio</surname><given-names>M</given-names></name><name><surname>Citterio</surname><given-names>A</given-names></name><name><surname>Spreafico</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome</article-title><source>Brain</source><volume>125</volume><fpage>1719</fpage><lpage>1732</lpage><pub-id pub-id-type="doi">10.1093/brain/awf175</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatton-Brown</surname><given-names>K</given-names></name><name><surname>Weksberg</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP</article-title><source>American Journal of Medical Genetics Part C</source><volume>163</volume><fpage>122</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1002/ajmg.c.31361</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibes</surname><given-names>R</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Hennessy</surname><given-names>B</given-names></name><name><surname>Andreeff</surname><given-names>M</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Kornblau</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells</article-title><source>Molecular Cancer Therapeutics</source><volume>5</volume><fpage>2512</fpage><lpage>2521</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0334</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Crino</surname><given-names>PB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>MTOR and epileptogenesis in developmental brain malformations</article-title><source>Epilepsia</source><fpage>835</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1093/med/9780199746545.003.0065</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>McIlroy</surname><given-names>J</given-names></name><name><surname>Rordorf-Nikolic</surname><given-names>T</given-names></name><name><surname>Orr</surname><given-names>GA</given-names></name><name><surname>Backer</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit</article-title><source>Molecular and Cellular Biology</source><volume>18</volume><fpage>1379</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1128/MCB.18.3.1379</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Stawiski</surname><given-names>E</given-names></name><name><surname>Janakiraman</surname><given-names>V</given-names></name><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Edgar</surname><given-names>KA</given-names></name><name><surname>Kljavin</surname><given-names>NM</given-names></name><name><surname>Rivers</surname><given-names>CS</given-names></name><name><surname>Gnad</surname><given-names>F</given-names></name><name><surname>Roose-Girma</surname><given-names>M</given-names></name><name><surname>Haverty</surname><given-names>PM</given-names></name><name><surname>Fedorowicz</surname><given-names>G</given-names></name><name><surname>Heldens</surname><given-names>S</given-names></name><name><surname>Soriano</surname><given-names>RH</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wallin</surname><given-names>JJ</given-names></name><name><surname>Johnson</surname><given-names>L</given-names></name><name><surname>Merchant</surname><given-names>M</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Stern</surname><given-names>HM</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations</article-title><source>Oncogene</source><volume>32</volume><fpage>318</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.53</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>LH</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Gutmann</surname><given-names>DH</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex</article-title><source>Annals of Neurology</source><volume>63</volume><fpage>444</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1002/ana.21331</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat</article-title><source>Epilepsia</source><volume>53</volume><fpage>506</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1167.2011.03384.x</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Vogt</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>105</volume><fpage>2652</fpage><lpage>2657</lpage><pub-id pub-id-type="doi">10.1073/pnas.0712169105</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Chow</surname><given-names>LM</given-names></name><name><surname>Bayazitov</surname><given-names>IT</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Gilbertson</surname><given-names>RJ</given-names></name><name><surname>Zakharenko</surname><given-names>SS</given-names></name><name><surname>Solecki</surname><given-names>DJ</given-names></name><name><surname>Baker</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Pten deletion causes mTorc1-dependent ectopic neuroblast differentiation without causing uniform migration defects</article-title><source>Development</source><volume>139</volume><fpage>3422</fpage><lpage>3431</lpage><pub-id pub-id-type="doi">10.1242/dev.083154</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.12703.025</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Morrison</surname><given-names>Sean J</given-names></name><role>Reviewing editor</role><aff id="aff6"><institution>Howard Hughes Medical Institute, University of Texas Southwestern Medical Center</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see <ext-link ext-link-type="uri" xlink:href="http://elifesciences.org/review-process">review process</ext-link>). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.</p></boxed-text><p>Thank you for choosing to send your work entitled &quot;Mouse models of human PIK3CA-related segmental overgrowth have treatment-responsive epilepsy&quot; for consideration at <italic>eLife</italic>. Your full submission has been evaluated by Sean Morrison (Senior Editor) and three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the decision was reached after discussions between the reviewers. Based on our discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in <italic>eLife</italic>.</p><p>In particular, while all three reviewers agreed that the work was potentially of interest, they felt that the characterization of the developmental phenotype was insufficient, and that it would require extensive new experimentation to make it rigorous enough for publication. In addition, the reviewers were concerned about the lack of insight into the epilepsy phenotype, with regard to cell biological mechanisms.</p><p><italic>Reviewer #1</italic>:</p><p>In this manuscript by Roy et al., the authors have examined the effects of hyperactivating PI3-kinase mutations on neural development, have compared these effects to those seen in humans carrying similar mutations, and have shown that inhibition of PI3-kinase activity can rescue the seizure phenotype seen in adult mice. In general, this is a nicely-performed study and the conclusions are interesting from a variety of perspectives. However, this manuscript could be significantly improved by a consideration of the following issues.</p><p>1) The authors have used a number of Cre driver lines to look at two different activating mutations in PIK3CA, H1047R and E545K. However, the strategies for driving expression of these mutant alleles are very different, with the former involving tet-inducible gene expression and the latter a cre-dependent knock-in allele. Since the <italic>E545K</italic> strategy mimics the human congenital mutations that the authors seek to model, and the <italic>H1047R</italic> is essentially an overexpression study and thus not as relevant, then the authors should really emphasize (and show) all of their findings with the <italic>E545K</italic> mutant, even though in many cases the differences are not as dramatic. For example, the experiments documenting neuronal colocalization with <italic>E545K</italic> are all shown in the supplementary data while those with the <italic>H1047R</italic> mutant are shown in the body of the paper in <xref ref-type="fig" rid="fig4">Figure 4</xref>. This should be reversed.</p><p>2) Some of the most interesting comparisons in this manuscript are those looking at different timepoints when the activating allele is expressed. However, in order to validate these comparisons, the authors need to show a comparison of the level of recombination that they are driving. I know that these are well-characterized cre driver lines, but having said that, there has been some drift with a number of these lines (for example the <italic>Nestin-cre</italic> mouse used here), and the authors really should provide their own data to validate the mutants they are studying.</p><p>3) The section on neuronal mislocalization is very interesting, but needs to be strengthened in a number of additional ways. First, the authors need to provide some kind of quantification, focusing on the <italic>E545K</italic> mutants, to solidify their data. This could be as simple as dividing the cortex into zones/layers (depending upon the age), and quantifying the proportion of layer-specific marker-positive cells that are in the different zones/layers in controls versus mutants. Second, the authors should remove their references to neuronal migration. They don't actually study migration anywhere in this manuscript, but instead study localization of neurons. Since, as they indicate in the discussion, these phenotypes could be due to many different developmental perturbations, to indicate that they are due to neuronal migration deficits is misleading.</p><p>4) The approach of RPPA to scan a large number of signaling proteins at once is a valuable one. Nonetheless, it is important that these changes be validated using other approaches. In particular, the authors should choose at least a few of the more important changes and verify them using western blots. If they all match the data obtained using RPPA, then this will validate the entire approach for these particular samples.</p><p><italic>Reviewer #2</italic>:</p><p>In this study the authors create animal models of megalencephaly (MEG) that are associated with mutations in PIK3CA. They first show that overexpression of PIK3CA in neural progenitors disrupts normal cortical development, and demonstrate that the timing of transgene activation is a critical feature of disease severity. They also demonstrate that overexpression of the two PIK3CA alleles leads to increased size of the cortex that is generally associated with an increase in nuclear and cell size and a decrease in cell density. They then demonstrate that the expanded cortex displays defects in lamination. As a consequence, transgenic animals overexpressing active alleles of PIK3CA are more prone to epileptic seizures. Finally, the authors show that a class I PI3K inhibitor has anti-seizure effects, and reduces phosphorylation of PI3K pathway components.</p><p>1) Validation of animal models. The authors need to show exactly when and where the p110a transgenes are expressed by their <italic>Nestin-cre, Nestin-creER</italic> and <italic>hGFAP-cre</italic> driver lines. Could there be differences in phenotypes from these different cre drivers based on level of expression, rather than simply due to the timing of cre activation? Also, the timing of tamoxifen administration for nestin-creER should be given in the results section to know when the transgenes were induced with this driver.</p><p>2) Comparisons of animal models. The authors do a nice job of presenting the different phenotypes associated with overexpression of the <italic>E545K</italic> allele achieved with the different <italic>cre</italic> drivers, but it would help to have more information on the <italic>H1047R</italic> allele. How does overexpression of <italic>H1047R</italic> affect brain size and morphology with the <italic>Nestin-creER</italic> and <italic>Nestin-cre</italic> lines? The authors stated that the most severe phenotype was achieved in <italic>hGFAP-cre;H1047R</italic> mtuants, but relative to what? To the other <italic>H1047R</italic> lines, or relative to <italic>E545K</italic> lines (or both)? If <italic>H1047R</italic> was only tested with the <italic>hGFAP-cre</italic> line, this should be clearly stated.</p><p><italic>Reviewer #3</italic>:</p><p>This manuscript describes the phenotype of mouse models with mutations in PIK3CA that should overactivate the PI3K-AKT pathway in the nervous system. The <italic>E545K</italic> and <italic>H1047R</italic> activating mutations have been found before in patients with cancer, but also with various forms of segmental cortical dysplasia. Corresponding mouse lines have been generated and investigated before for studying the role of these activating mutations in cancer. In this study, the authors have used <italic>Nestin-Cre</italic> and <italic>GFAP-Cre</italic> for nervous system-specific induction of the mutant alleles, and these mice developed enlarged brain size, cortical dysplasia and epilepsy. The authors find that <italic>GFAP-Cre H1047R</italic> mutants show a very severe phenotype with progressive hydrocephalus and death around birth. Mice with <italic>E545K</italic> mutation and the same <italic>GFAP-Cre</italic> driver were less affected. Earlier developmental induction of the <italic>E545K</italic> mutation with <italic>Nestin-Cre</italic> showed a more severe phenotype than that observed after <italic>GFAP-Cre</italic>-mediated activation. The authors then found that the inner cortical length of <italic>GFAP-Cre H1047R</italic> mutants at E14-E16 was longer than in controls. Surprisingly, increased proliferation was not observed in these animals, only enlarged cell size. Interestingly, the <italic>Nestin-Cre E545K</italic> mutants showed enhanced proliferation with reduced cortical thickness, indicating that the newborn cells did not adequately migrate. The authors also observed dysplastic Cajal-Retzius cells in <italic>GFAP-Cre H1047R</italic> mice at E16. They then investigated <italic>Nestin-Cre</italic> and Tamoxifen-inducible <italic>Nestin-Cre E545K</italic> mutant mice for abnormalities in EEG and found signs of epileptiform activity, in particular when induced with the GABA-A receptor antagonist PTZ. The authors then also provide evidence that the PI3K inhibitor BKM-120 suppresses seizure activity and shows some effects on parameters of PI3K pathway activation.</p><p>Although these data are of potential interest to understand the molecular basis of segmental cortical dysplasia in humans, the paper is largely descriptive and the mechanisms how PI3K activation induces this complex disorganization of cortical development that then results in altered excitability and epileptic seizures is not explained. It is even unclear whether alterations in cell division, cell cycle exit, migration, terminal differentiation, spontaneous activity and synaptic plasticity occur in these mice. It is unclear whether <italic>GFAP-Cre</italic> and <italic>Nestin-Cre</italic> act in the same or in distinct precursor cell populations, whether defects in all types of neurons, or only specific subtypes, or defects in astrocytes cause this specific phenotype. The latter is possible in particular in <italic>GFAP-Cre</italic> mice. The previous paper by Robinson et al. in Nature 2012 showed that the same E545K mutation, when induced with <italic>Blbp-Cre</italic> in lower rhombic lip progenitors accelerates tumor generation, but does not per se initiate WNT subgroup medulloblastoma. This leaves the question open whether the same mutation in <italic>Nestin</italic>- or <italic>GFAP-Cre</italic> expressing cells causes defects that need additional signals to develop the pathogenic phenotype.</p><p>Additional specific comments:</p><p>1) The paper lacks clear evidence about the types of cells in which the mutant PIK3CA isoforms are expressed, and at which stage of development recombination occurs. This is necessary to explain whether dysregulated PIK3CA causes abnormalities in division of neural precursor cells. I wonder why the authors did not do more detailed pulse chase experiments with BrdU to study potential effects on altered proliferation of different types of precursor cells in the ventricular and subventricular zone. It would also be important to know whether proliferation of neuronal cells is differentially affected in comparison to proliferation of astrocytic precursor cells. At E16.5, the time point when the analyses shown in <xref ref-type="fig" rid="fig2">Figure 2</xref> were performed, proliferation of astrocytes has already started, and the authors should do the studies shown in <xref ref-type="fig" rid="fig3">Figure 3</xref> with markers that can distinguish neuronal from astrocytic precursor cells.</p><p>2) It is hard to explain why the cell density, as shown in <xref ref-type="fig" rid="fig3">Figure 3p</xref> is reduced when BrdU incorperation is increased. It is also not clear in which layers of the cortex the authors observe this reduced cell density at E16.5. To understand this phenotype, the VZ/SVZ, the mantle zone and the intermediate zone should be investigated separately. Did the authors also investigate whether there is enhanced loss of cells by apoptosis or other types of cell death between E14.5 and E16.5 to explain this phenotype?</p><p>3) The phenotype with increased cell size is hard to explain. This could be due to a defect in the cell fate determination of distinct populations of neuronal types, for example when generation and survival of pyramidal cells in comparison to interneurons is enhanced, or also by altered generations of neurons in comparison to glial cells. In order to understand the phenotype of altered cortical morphology and enhanced epileptic seizures, this would be important to know.</p><p>4) There is a big gap between the defects in cortical thickness and the potential mechanisms that could explain the altered threshold for epileptic seizures. Is there a dysbalance between GABAergic and glutamatergic neurons and synapses in the brain of these mice? Is there defective regulation of synapse generation, function and plasticity? Are there defects in dendritic arborization and synaptogenesis? Are there differences in the morphology of astrocytes and differences in gene expression in such astrocytes, i.e. for neurotransmitter transporters, that could explain the epileptiform activity?</p><p>5) It is not clear whether the enhanced epileptiform activity reflects a developmental defect or altered synaptic activity, which is directly driven by altered PIK3CA activation. The authors have used both a constitutive <italic>Nestin-Cre</italic> and a Tamoxifen-inducible Cre driver, but there are no data to distinguish the phenotype when E545K mutant PIK3CA is expressed from developmental stages, or only after acute induction in the adult.</p><p>Other questions and points of concern:</p><p>1) In the Materials and methods section, the authors say that all mouse lines were maintained on a mixed genetic background. It is not clear what this means and whether differences in genetic background could influence the phenotype. How can the authors exclude the possibility that the more severe phenotype observed in the <italic>GFAP-Cre</italic> drivers in comparison to <italic>Nestin-Cre</italic> drivers is due to different genetic background?</p><p>2) The data shown in <xref ref-type="fig" rid="fig5">Figure 5d</xref> are very hard to understand and not well described. What is the function of time at which the numbers of seizures occur? Does the diagram mean seizures within one minute? These bars lack standard deviations. How can one understand i.e. 0.4 seizures or 1.6 seizures per minute and why does the number of seizures fluctuate with a peak at 7 min., 15 and 22 min. after PTZ injection? Which phase of seizure activity is affected by BKM-120-treatment? Obviously, the PI3K inhibitor does not reduce seizure activity completely.</p><p>3) The data shown in <xref ref-type="fig" rid="fig6">Figure 6</xref> are hard to understand, given that the differences are generally much lower than expected, and it is also not clear which types of cells and which subpopulations of neurons are predominantly affected by altered Akt phosphorylation or other downstream signaling parameters that are expected to be altered when the PI3-K pathway is constitutively activated.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.12703.026</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>Reviewer #1:</p><p> <italic>In this manuscript by Roy et al., the authors have examined the effects of hyperactivating PI3-kinase mutations on neural development, have compared these effects to those seen in humans carrying similar mutations, and have shown that inhibition of PI3-kinase activity can rescue the seizure phenotype seen in adult mice. In general, this is a nicely-performed study and the conclusions are interesting from a variety of perspectives. However, this manuscript could be significantly improved by a consideration of the following issues. 1) The authors have used a number of Cre driver lines to look at two different activating mutations in PIK3CA, H1047R and E545K. However, the strategies for driving expression of these mutant alleles are very different, with the former involving tet-inducible gene expression and the latter a cre-dependent knock-in allele. Since the E545K strategy mimics the human congenital mutations that the authors seek to model, and the H1047R is essentially an overexpression study and thus not as relevant, […]</italic></p><p>The <italic>H1047R</italic> allele is <italic>not</italic> functionally an overexpression allele. The PI3K enzyme is made of p110 (encoded by Pik3ca) and p85 subunits. Previous publications have demonstrated that p110 stability is dependent on levels of p85 (Fruman et al., 2000; Yu et al., 1998). Geering et al., 2007 demonstrated that there is no evidence of free p110 or free p85 subunits in mammalian cell lines and tissues. Thus, both the <italic>E545K</italic> and <italic>H1047R</italic> alleles are relevant to model human <italic>PIK3CA</italic> mutations.</p><p><italic>[…] then the authors should really emphasize (and show) all of their findings with the E545K mutant, even though in many cases the differences are not as dramatic. For example, the experiments documenting neuronal colocalization with E545K are all shown in the supplementary data while those with the H1047R mutant are shown in the body of the paper in <xref ref-type="fig" rid="fig4">Figure 4</xref>. This should be reversed.</italic> </p><p>We have included data from both alleles throughout the main figures.</p><p><italic>2) Some of the most interesting comparisons in this manuscript are those looking at different timepoints when the activating allele is expressed. However, in order to validate these comparisons, the authors need to show a comparison of the level of recombination that they are driving. I know that these are well-characterized cre driver lines, but having said that, there has been some drift with a number of these lines (for example the nestin-cre mouse used here), and the authors really should provide their own data to validate the mutants they are studying.</italic> We have included cre control data as <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref></p><p><italic>3) The section on neuronal mislocalization is very interesting, but needs to be strengthened in a number of additional ways. First, the authors need to provide some kind of quantification, focusing on the E545K mutants, to solidify their data. This could be as simple as dividing the cortex into zones/layers (depending upon the age), and quantifying the proportion of layer-specific marker-positive cells that are in the different zones/layers in controls versus mutants.</italic> </p><p>We provide extensive new quantitation in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</p><p><italic>Second, the authors should remove their references to neuronal migration. They don't actually study migration anywhere in this manuscript, but instead study localization of neurons. Since, as they indicate in the discussion, these phenotypes could be due to many different developmental perturbations, to indicate that they are due to neuronal migration deficits is misleading.</italic> Our new birthdating experiments (<xref ref-type="fig" rid="fig6">Figure 6</xref>) now provide extensive support for migration deficits.</p><p><italic>4) The approach of RPPA to scan a large number of signaling proteins at once is a valuable one. Nonetheless, it is important that these changes be validated using other approaches. In particular, the authors should choose at least a few of the more important changes and verify them using western blots. If they all match the data obtained using RPPA, then this will validate the entire approach for these particular samples.</italic> </p><p>The amount of mutant tissue available from the brain of the mice was limiting, particularly given the different assays that were performed on the tissues. RPPA requires very small amounts of tissue to perform multiplex analysis across many antibodies and was thus the most tissue sparing approach available. Several studies have demonstrated that RPPA is more sensitive than standard Western blotting and is becoming a standard assay in cancer biology (Akbani et al., 2014; Tibes et al., 2006; Gujral et al., 2013; Hennessy et al., 2010; Nishizuka et al., 2003). Indeed the RPPA facility has used this specific panel on more than 100,000 samples (Gordon Mills, our co-author, runs this facility and has published extensively on RPPA). Well over 100 papers including almost all of the TCGA (<underline>T</underline>he <underline>C</underline>ancer <underline>G</underline>enome <underline>A</underline>tlas project) papers have used RPPA analysis and indeed, no confirmation western blots have been requested for the complete TCGA set due to the extensive validation in other sample sets. The three independent biological replicates per sample further support data validity. Unfortunately, insufficient mutant brain tissue was available to perform western blots at the end of the study and thus we had to rely on the results from the RPPA analysis.</p><p>Reviewer #2:</p><p><italic>In this study the authors create animal models of megalencephaly (MEG) that are associated with mutations in PIK3CA. They first show that overexpression of PIK3CA in neural progenitors disrupts normal cortical development, and demonstrate that the timing of transgene activation is a critical feature of disease severity. They also demonstrate that overexpression of the two PIK3CA alleles leads to increased size of the cortex that is generally associated with an increase in nuclear and cell size and a decrease in cell density. They then demonstrate that the expanded cortex displays defects in lamination. As a consequence, transgenic animals overexpressing active alleles of PIK3CA are more prone to epileptic seizures. Finally, the authors show that a class I PI3K inhibitor has anti-seizure effects, and reduces phosphorylation of PI3K pathway components.</italic> </p><p> <italic>1) Validation of animal models. The authors need to show exactly when and where the p110a transgenes are expressed by their nestin-cre, nestin-creER and hGFAP-cre driver lines. Could there be differences in phenotypes from these different cre drivers based on level of expression, rather than simply due to the timing of cre activation? Also, the timing of tamoxifen administration for nestin-creER should be given in the results section to know when the transgenes were induced with this driver.</italic> </p><p>Cre validation is now provided in <xref ref-type="fig" rid="fig1s2">Figure 1— figure supplement 2</xref>.</p><p><xref ref-type="fig" rid="fig1">Figure 1</xref> clearly shows that it is not the cre line that affects the phenotype per se. It is the nature of the specific mutant allele as well as the time of activation of the mutation in brain that result in the developmental phenotypes. For example, if we compare the <italic>E545K</italic> and <italic>H1047R</italic> mutants, both activated by <italic>hGFAP-cre</italic>, we observe that the <italic>hGFAP-cre;H1047R</italic> mutant has hydrocephalus and agenesis of corpus callosum, while neither of these phenotypes are observed in <italic>hGFAP-cre;E545K</italic> mutant.</p><p><italic>2) Comparisons of animal models. The authors do a nice job of presenting the different phenotypes associated with overexpression of the E545K allele achieved with the different cre drivers, but it would help to have more information on the H1047R allele. How does overexpression of H1047R affect brain size and morphology with the Nestin-creER and nestin-cre lines? The authors stated that the most severe phenotype was achieved in hGFAP-cre;H1047R mtuants, but relative to what? To the other H1047R lines, or relative to E545K lines (or both)? If H1047R was only tested with the hGFAP-cre line, this should be clearly stated.</italic> </p><p>We have rephrased this in the text. We meant among all the mutants studied in this paper, irrespective of allele or cre line, <italic>hGFAP-cre;H1047R</italic> mutants show the most severe developmental defects in the brain.</p><p>Reviewer #3:</p><p> <italic>This manuscript describes the phenotype of mouse models with mutations in PIK3CA that should overactivate the PI3K-AKT pathway in the nervous system. The E545K and H1047R activating mutations have been found before in patients with cancer, but also with various forms of segmental cortical dysplasia. Corresponding mouse lines have been generated and investigated before for studying the role of these activating mutations in cancer. In this study, the authors have used Nestin-Cre and GFAP-Cre for nervous system-specific induction of the mutant alleles, and these mice developed enlarged brain size, cortical dysplasia and epilepsy. The authors find that GFAP-Cre H1047R mutants show a very severe phenotype with progressive hydrocephalus and death around birth. Mice with E545K mutation and the same GFAP-Cre driver were less affected. Earlier developmental induction of the E545K mutation with Nestin-Cre showed a more severe phenotype than that observed after GFAP-Cre-mediated activation. The authors then found that the inner cortical length of GFAP-Cre H1047R mutants at E14-E16 was longer than in controls. Surprisingly, increased proliferation was not observed in these animals, only enlarged cell size. Interestingly, the Nestin-Cre E545K mutants showed enhanced proliferation with reduced cortical thickness, indicating that the newborn cells did not adequately migrate. The authors also observed dysplastic Cajal-Retzius cells in GFAP-Cre H1047R mice at E16. They then investigated Nestin-Cre and Tamoxifen-inducible Nestin-Cre E545K mutant mice for abnormalities in EEG and found signs of epileptiform activity, in particular when induced with the GABA-A receptor antagonist PTZ. The authors then also provide evidence that the PI3K inhibitor BKM-120 suppresses seizure activity and shows some effects on parameters of PI3K pathway activation. Although these data are of potential interest to understand the molecular basis of segmental cortical dysplasia in humans, the paper is largely descriptive and the mechanisms how PI3K activation induces this complex disorganization of cortical development that then results in altered excitability and epileptic seizures is not explained. It is even unclear whether alterations in cell division, cell cycle exit, migration, terminal differentiation, spontaneous activity and synaptic plasticity occur in these mice.</italic> </p><p>We concur that we have extensively described the first models of human <italic>PIK3CA</italic> related brain malformations – a clinically important class of cortical malformations with an impressive phenotypic spectrum – from dysplastic megalencephaly to focal cortical dysplasia. Our mouse models recapitulate the human phenotypes and demonstrate validity of our models. Further we demonstrate that the mice display epilepsy – perhaps the most clinically relevant phenotype in this population. Since these are the first models, extensive phenotypic description was required.</p><p>Mechanistically, we counter that we have indeed defined the developmental basis of megalencephaly and cortical dysplasia, showing alterations in proliferation, cell cycle exit, cell migration versus cell fate, and cell size (<xref ref-type="fig" rid="fig3">Figures 3</xref>, <xref ref-type="fig" rid="fig6">6</xref>). While these phenotypes are important, the major significant finding of our work is that the cortical dysplasia is less relevant to epilepsy than previously thought. Developmentally, we can dissociate dysmorphology from epilepsy. Mice with abnormal neocortical cell distribution (<italic>Nestin-cre;E545K</italic>) as well as those without dysplasia (<italic>Nestin-creER;E545K</italic>) exhibit epilepsy. Further, we can acutely treat the epilepsy in mice even with severe dysplasia.</p><p>As we have now more lucidly argued in the Introduction and Discussion, the finding that Pik3ca-driven epilepsy is an active process, amenable to acute intervention is a major advance. Mechanistically, acute treatment with BKM120 alters mTOR-dependent phosphorylation of AKT with strong effects in the mutant hippocampus. Given the extensive developmental analyses presented in addition to the epilepsy data, we consider further analysis of the synaptic physiology and the dissection of pAKT-dependent and/or pAKT-independent pathways that underlie the epilepsy to be well beyond the scope of the current manuscript.</p><p><italic>It is unclear whether GFAP-Cre and Nestin-Cre act in the same or in distinct precursor cell populations, whether defects in all types of neurons, or only specific subtypes, or defects in astrocytes cause this specific phenotype. The latter is possible in particular in GFAP-Cre mice.</italic> </p><p>Please see <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> for differential expression pattern of <italic>hGFAP-cre</italic> and <italic>Nestin-cre</italic> lines. These two lines express in overlapping but distinct cell populations. Moreover, when we compare <italic>Nestin-cre;E545K</italic> and <italic>hGFAP-cre;E545K</italic> we see they have comparable morphological phenotypes while <italic>hGFAP-cre;H1047R</italic> is quite different. This confirms that differential phenotype is dependent on the specific mutant allele even when same cre line is used.</p><p><italic>The previous paper by Robinson et al. in Nature 2012 showed that the same E545K mutation, when induced with Blbp-Cre in lower rhombic lip progenitors accelerates tumor generation, but does not per se initiate WNT subgroup medulloblastoma. This leaves the question open whether the same mutation in Nestin- or GFAP-Cre expressing cells causes defects that need additional signals to develop the pathogenic phenotype.</italic> </p><p>We are unclear regarding the nature of the reviewer’s concern. We demonstrate that <italic>E545K</italic> mutation driven by either <italic>Nestin-cre</italic> or <italic>hGFAP-cre</italic>, result in megalencephaly, cortical and white matter dysplasia. The nature and extent of dysplasia depends on the developmental timing. We have also provided two genetic models of epilepsy caused by the <italic>E545K</italic> mutation; and we show seizure activity can be acutely suppressed by a pan-Class I PI3K inhibitor, BKM120. Moreover, we provide RPPA protein analyses which show that the protein levels are dynamically regulated by acute administration of the drug. These data conclusively show that activation of PIK3ca <italic>alone</italic> is sufficient to give rise to different developmental defects including epilepsy.</p><p> <italic>Additional specific comments: 1) The paper lacks clear evidence about the types of cells in which the mutant PIK3CA isoforms are expressed, and at which stage of development recombination occurs. This is necessary to explain whether dysregulated PIK3CA causes abnormalities in division of neural precursor cells.</italic> </p><p>We have included cre control data as <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</p><p><italic>I wonder why the authors did not do more detailed pulse chase experiments with BrdU to study potential effects on altered proliferation of different types of precursor cells in the ventricular and subventricular zone. It would also be important to know whether proliferation of neuronal cells is differentially affected in comparison to proliferation of astrocytic precursor cells. At E16.5, the time point when the analyses shown in <xref ref-type="fig" rid="fig2">Figure 2</xref> were performed, proliferation of astrocytes has already started, and the authors should do the studies shown in <xref ref-type="fig" rid="fig3">Figure 3</xref> with markers that can distinguish neuronal from astrocytic precursor cells.</italic> </p><p>We have now included detailed BrdU-pulse experiments to study proliferation (1 hour pulse), cell cycle exit (1 day pulse) and birthdating early and late neurogenesis (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig6">Figure 6</xref>). We have also quantitated the differential BrdU distribution in control and mutant littermates in different zones of the cortical column. We have qualitatively shown that the <italic>Pik3ca E545K</italic> mutation does not affect astrocyte shape, size or number (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>). More detailed astrocyte analysis was deemed beyond the scope of the current study.</p><p><italic>2) It is hard to explain why the cell density, as shown in <xref ref-type="fig" rid="fig3">Figure 3p</xref> is reduced when BrdU incorperation is increased. It is also not clear in which layers of the cortex the authors observe this reduced cell density at E16.5. To understand this phenotype, the VZ/SVZ, the mantle zone and the intermediate zone should be investigated separately.</italic> </p><p>In E16.5 <italic>Nestin-cre;E545K</italic>, multiple cellular mechanisms collectively affect the final phenotype. E16.5 <italic>E545K</italic> mutant has increased labeling index (indicating increased proliferation, <xref ref-type="fig" rid="fig3">Figure 3r</xref>) as well as increased cortical length (<xref ref-type="fig" rid="fig2">Figure 2m</xref>). The cortical density at E16.5 is not distinctly lower in any particular zone. Additionally at a later developmental time-point P0, we quantitate number of cells in different zones of the cortical column, as described in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</p><p><italic>Did the authors also investigate whether there is enhanced loss of cells by apoptosis or other types of cell death between E14.5 and E16.5 to explain this phenotype?</italic> </p><p>See reply to Reviewer #2’s comment 6: In <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> our mutants actually show slight decreases in cell death during embryonic peak neurogenesis.</p><p><italic>3) The phenotype with increased cell size is hard to explain. This could be due to a defect in the cell fate determination of distinct populations of neuronal types, for example when generation and survival of pyramidal cells in comparison to interneurons is enhanced, or also by altered generations of neurons in comparison to glial cells. In order to understand the phenotype of altered cortical morphology and enhanced epileptic seizures, this would be important to know.</italic> </p><p>mTOR overactivation is known to cause increased cell size (Blumcke et al., 2011; Fingar et al., 2002; Lim et al., 2015; Ljungberg et al., 2006). As we have indicated in the Discussion, in human <italic>PIK3CA</italic> brains and in cultured rodent hippocampal neurons overexpressing Pik3ca, cell size is increased, but not to the extent seen with TSC mutation, PTEN deletion, or pAKT activation.</p><p>We see no evidence of changes in cell fate (<xref ref-type="fig" rid="fig6">Figure 6</xref>). There is a temporal dependence on cell size, with postnatal <italic>Pik3ca</italic> activation having no effect on cell size (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Thus, altered cell size cannot be a common basis of epilepsy in our models as both models exhibit epilepsy.</p><p>Interneurons are born at embryonic stages and their migration is almost complete before birth. Postnatal activation of <italic>Nestin-creER;E545K</italic> does not cause increased cell size or megalencephaly. The YFP-positive cells marking the cells in this model that express mutant PiK3ca do not coexpress interneuron markers like Parvalbumin and Somatostatin (data not shown). Altered interneuron development in mice where mutant <italic>Pik3ca</italic> is activated embryonically (<italic>Nestin-cre;E545K</italic>) may contribute to dysmorphology. However, this does not seem to be the common mechanism behind epilepsy since both embryonic and postnatal <italic>Pik3ca</italic> activation causes epilepsy.</p><p><italic>4) There is a big gap between the defects in cortical thickness and the potential mechanisms that could explain the altered threshold for epileptic seizures. Is there a dysbalance between GABAergic and glutamatergic neurons and synapses in the brain of these mice? Is there defective regulation of synapse generation, function and plasticity? Are there defects in dendritic arborization and synaptogenesis? Are there differences in the morphology of astrocytes and differences in gene expression in such astrocytes, i.e. for neurotransmitter transporters, that could explain the epileptiform activity?</italic> </p><p>Although we have extensively characterized the cortical dysmorpholgy in our models, our observation that the epilepsy is acutely sensitive to treatment <italic>despite dysmorphology</italic> argues that it is an active Pik3ca-dependent process. This is a major and paradigm shifting finding. Given the extensive developmental analyses presented in addition to the epilepsy data, we consider further analysis of the synaptic physiology and the dissection of pAKT-dependent and/or pAKT-independent pathways that underlie the epilepsy to be well beyond the scope of the current manuscript; however they are the focus of ongoing studies in our lab.</p><p><italic>5) It is not clear whether the enhanced epileptiform activity reflects a developmental defect or altered synaptic activity, which is directly driven by altered PIK3CA activation. The authors have used both a constitutive Nestin-Cre and a Tamoxifen-inducible Cre driver, but there are no data to distinguish the phenotype when E545K mutant PIK3CA is expressed from developmental stages, or only after acute induction in the adult.</italic></p><p>While developmental defects may contribute to Pik3ca-driven epilepsy, our combined data from multiple models argue that the developmental defects are not the major drivers. Morphological differences between embryonic and postnatal E545K activation are summarized in <xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="table" rid="tbl1">Table 1</xref>.</p><p><italic>Other questions and points of concern: 1) In the methods section, the authors say that all mouse lines were maintained on a mixed genetic background. It is not clear what this means and whether differences in genetic background could influence the phenotype. How can the authors exclude the possibility that the more severe phenotype observed in the GFAP-Cre drivers in comparison to Nestin-Cre drivers is due to different genetic background?</italic> </p><p>We have rewritten the Materials and methods section to clarify the nature of the mixed background. Data presented in <xref ref-type="fig" rid="fig1">Figure 1</xref> demonstrates that the genetic background of mice does not broadly affect Pik3ca-related phenotypes.</p><p><italic>2) The data shown in <xref ref-type="fig" rid="fig5">Figure 5d</xref> are very hard to understand and not well described. What is the function of time at which the numbers of seizures occur? Does the diagram mean seizures within one minute? These bars lack standard deviations. How can one understand i.e. 0.4 seizures or 1.6 seizures per minute and why does the number of seizures fluctuate with a peak at 7 min., 15 and 22 min. after PTZ injection? Which phase of seizure activity is affected by BKM-120-treatment? Obviously, the PI3K inhibitor does not reduce seizure activity completely.</italic> </p><p>We have clarified the figure in the text and figure legend. During the 30 min after PTZ injection, mice experience several seizures. For each mouse we counted the number of seizures that they experience in one min bins to capture the complete seizure burden during our experiments. Therefore, the histogram is a representation of the average number of seizures that mice within control and mutant groups experience post-PTZ administration in 1 minute bins. These are population averages, with periodic fluctuations reflecting postictal refractory periodicity (Lado et al., 2008). Overall statistical analyses are presented in <xref ref-type="fig" rid="fig7">Figure 7h,i</xref>. BKM120 reduces total number of seizures, seizure severity and increases latency post-PTZ administration. BKM120 normalizes PTZ-induced seizures to untreated control (non-mutant) values.</p><p><italic>3) The data shown in <xref ref-type="fig" rid="fig6">Figure 6</xref> are hard to understand, given that the differences are generally much lower than expected, and it is also not clear which types of cells and which subpopulations of neurons are predominantly affected by altered Akt phosphorylation or other downstream signaling parameters that are expected to be altered when the PI3-K pathway is constitutively activated.</italic></p><p>PI3K signaling is highly regulated through feedback and feed-forward loops. As we have stated in the Discussion, our proteomics data is congruent with published breast cancer data showing that even high levels PI3K pathway overactivation only causes modest changes in the levels of steady-state PI3K signaling. Our cre validation data shows cell populations predominantly affected in each mutant.</p><p>References:</p><p>R. Akbani et al., Mol Cell Proteomics 13, 1625 (2014).</p><p>T. S. Gujral et al., Oncogene 32, 3470 (2013).</p><p>B. T. Hennessy et al., Clin Proteomics 6, 129 (2010).</p><p>S. Nishizuka et al., Proc Natl Acad Sci U S A 100, 14229 (2003).</p><p>D. C. Fingar, S. Salama, C. Tsou, E. Harlow, J. Blenis, Genes Dev 16, 1472 (2002).</p><p>M. C. Ljungberg et al., Ann Neurol 60, 420 (2006).</p><p>F. A. Lado, S. L. Moshe, Epilepsia 49, 1651 (2008).</p></body></sub-article></article>